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ABSTRACT 
 
Wilson disease protein (ATP7B) is a P-type ATPase that catalyzes the transport of copper 
across cell membranes and is critical for maintaining copper homeostasis.  ATP7B   contains an 
N-terminal metal binding module that is found only in heavy metal transporters.  The N-terminal 
region is composed of six metal-binding domains (MBD1-6) joined together by flexible linkers.  
Each MBD is approximately 70 amino acids and contains the signature motif, CXXC, with one 
Cu(I) binding between two cysteines.  The structures of the individual MBDs have been solved, 
however, the dynamics and arrangement of the individual MBDs in the full-length protein were 
unknown.  Gaining insights into the conformation and dynamics of this unique region helps us 
understand how the enzymatic and trafficking activity of ATP7B is regulated.  In our study, we 
used recombinant single domain camelid antibodies, also known as nanobodies, to reveal 
functionally relevant transient interactions within a distinct group of MBDs.  We identified new 
transient interactions between metal-binding domains 1, 2, and 3 and provided independent 
evidence for structurally and functionally distinct roles for MBD5-6.  We demonstrated that 
nanobodies were used as effective probes for investigating molecular dynamics of multi-domain 
proteins.   
 
Overexpression of ATP7B is associated with tumor resistance to cisplatin during 
chemotherapy.  Cisplatin kills cancer cells by reacting with DNA, which prevents proper DNA 
transcription and replication.  ATP7B was proposed to actively transport cisplatin out of the cell, 
however, low transport rates in physiological pH and high substrate specificity for copper 
suggests that cisplatin detoxification by active extrusion is unlikely.  Rather, we proposed that 
the metal-binding domains in ATP7B functioned as a high-affinity reservoir by trapping cisplatin 
and then releasing it to other potential terminal acceptors in a non-toxic form.  We used NMR 
spectroscopy to characterize cisplatin binding to metal-binding domain 2 (MBD2) of ATP7B.  
We demonstrated that platinum is transferred from Atox1 to MBD2 in a mechanism that parallels 
the copper-transport pathway in the cell, which suggested a possible route for cisplatin 
detoxification.  Platinum was subsequently released to other terminal acceptors such as 
glutathione and glutaredoxin, which demonstrated that the metal-binding domains may not be the 
final destination for cisplatin.    
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1 Introduction 
Copper is an essential trace element that mediates many cellular processes in living 
organisms including iron uptake, respiration, and radical detoxification.  However, there are 
severe consequences when excess copper is not properly exported from the cell.  Excess copper 
catalyzes the formation of reactive oxygen species that in turn cause protein malfunction and 
DNA mutations.  
 
ATP7B is a P1B-type ATPase that maintains copper homeostasis in the body.  ATP7B 
uses the energy of ATP hydrolysis to translocate copper ions across the cell membrane.  This 
copper transporter has two main functions in the liver, the tissue where ATP7B is primarily 
expressed.  ATP7B transports copper into the secretory pathway for incorporation into copper-
dependent enzymes.  Another function of ATP7B involves excreting excess copper from the cell 
into bile.   Mutations in ATP7B result in a severe disorder known as Wilson disease.  Wilson 
disease is characterized by copper accumulation primarily in the liver and, if left untreated, 
severe hepatic disease and eventual death will occur.  
 
 ATP7B consists of a single polypeptide made up of several distinct domains.  However, 
the most characteristic feature of heavy metal transporters is the N-terminal region containing six 
metal-binding domains.  The N-terminal region functions by regulating copper transport and 
trafficking activity of ATP7B.  The structures for all the individual metal-binding domains have 
been solved, but the arrangement of the individual metal-binding domains in the context of full-
length MBD1-6 was unknown.  Therefore, our main goal in this project was to examine the 
conformation and dynamics of MBD1-6 using high-resolution NMR spectroscopy.           
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2 Review of the literature 
2.1 Physiological role of copper 
2.1.1 Copper distribution and metabolism 
 Copper is an essential trace element that is required by living organisms in all the five 
kingdoms of life for proper growth and development.  Copper mediates many biological 
functions in human cells by serving as a cofactor for numerous enzymes such as cytochrome 
oxidase, superoxide dismutase, and dopamine-β-hydroxlase (Lutsenko et al., 2007).  The fast 
interconversion from oxidized Cu(II) to reduced Cu(I), and vice versa, allows copper to 
participate in many important biological redox reactions which include iron uptake, electron and 
oxygen transport, and radical detoxification (Lutsenko et al., 2007).  However, excess copper is 
very toxic, catalyzing the formation of reactive oxygen species through the Haber-Weiss and 
Fenton reactions: 
O2•- + Cu2+ à O2 + Cu+  (Haber-Weiss)                            (2.1) 
 Cu+ + H2O2 à Cu2+ + HO• + OH-  (Fenton reaction)                        (2.2) 
 O2•- + H2O2 à O2 + HO• + OH-   (Net reaction)                              (2.3) 
Reducing agents such as glutathione or ascorbate catalyze the conversion of Cu2+ to Cu+ 
(reaction 2.1).  Copper(I) spontaneously catalyzes the reaction with hydrogen peroxide (H2O2) to 
form the highly reactive hydroxyl radicals (HO•) and anions (OH-) (reaction 2.2).  These 
reactive oxygen species can cause DNA mutations and protein malfunction.  Therefore, 
mechanisms for maintaining copper homeostasis are critical for cell survival.    
  
 Dietary copper is absorbed by enterocytes in the small intestine and transported across 
the apical membrane by human copper transporter 1 (hCtr1) (Figure 2.1).  In the enterocyte, 
copper chaperone antioxidant protein 1 (Atox1) binds and transports copper to Menkes disease 
Protein (ATP7A) (Hamza et al., 1999).  As the copper concentration increases, ATP7A traffics to 
the basolateral membrane of the enterocyte and transports copper into the portal and general 
blood circulation (Ravia et al., 2005).  In the bloodstream, copper is bound to serum proteins 
such as albumin and transcuprein (Linder, 1996).  A majority of the copper in the bloodstream 
travels directly to the liver, and a smaller portion goes to the kidneys (Linder, 1996).   
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The liver is the major organ responsible for regulating copper homeostasis in the body.  
Wilson disease protein (ATP7B), a homologue of ATP7A, regulates the export of copper from 
the liver into the peripheral blood circulation.  ATP7B has two main functions in the cell.  It 
transports copper into the lumen of the trans-Golgi network (TGN) for incorporation into 
copper-dependent enzymes or it transports excess copper into bile for excretion (Lutsenko et al., 
2007).    
 
Figure 2.1: Copper distribution in the body.  Under normal copper conditions, dietary copper 
(yellow spheres) is mainly absorbed in the small intestine and transported into the blood 
circulation by ATP7A.  A majority of the copper entering the bloodstream goes to the liver and a 
smaller amount of copper goes to the kidneys.  ATP7B transports excess copper to bile and to 
copper-dependent enzymes such as ceruloplasmin and albumin for peripheral blood circulation.  
Copper is transported into peripheral tissues that express ATP7A.   
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2.1.2 Intracellular trafficking of copper 
 Copper distribution in the cell is a tightly regulated process.  Copper enters the cell by 
passive transport through hCtr1, a high-affinity copper channel in the plasma membrane.  The 
hCtr1 monomer is 190 amino acids long and oligomerizes to a trimer to form the copper uptake 
pore (de Feo et al., 2009) (Figure 2.2A).  It contains several characteristic sequence motifs that 
are involved in copper binding and transport through the cell membrane (Figure 2.2B).  The N-
terminal region contains histidine- and methionine-rich motifs that function in high-affinity 
copper uptake.  These motifs capture copper ions in the extracellular space and transfer it 
towards the transmembrane pore.  The second transmembrane domain contains the essential 
MxxxM motif that binds copper in the membrane and the third transmembrane domain contains 
a GxxxG motif that functions in helix packing and oligomerization (de Feo et al., 2009).   
 
Since the transmembrane region contains only one copper-binding site near the 
extracellular side of the membrane, how does copper reach the cytoplasm?  The authors 
proposed that binding of copper to the MxxxM binding site in TM2 triggers specific 
conformational changes that release copper to the C-terminal region (de Feo et al., 2009).  The 
C-terminal region of hCtr1 contains an HCH motif, which has been proposed to function as a 
high-affinity copper sink that binds and directly transfers Cu(I) to chaperone proteins (de Feo et 
al., 2009).   
 
Figure 2.2: Structural model of hCtr1.  (A) Side view of monomeric hCtr1 forming a pore in 
the membrane.  (B) The sequence topology for the characteristic motifs of hCtr1 is highlighted 
(red).      
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The transfer of copper from hCtr1 to chaperone proteins is still a matter of debate.  It was 
recently proposed that hCtr1 transfers Cu(I) to an exchangeable pool of copper-bound 
glutathione (GSH) (Maryon et al., 2013).  GSH would function as an intermediary for chaperone 
proteins such as Atox1 to acquire Cu(I) (Figure 2.3; red dashed arrows).  Copper chaperone 
proteins would have to search through the large cell volume and interact with Cu(I)-bound GSH 
in an orientation that is favorable for copper transfer.  Instead, it was proposed that Atox1 
directly acquires Cu(I) from hCtr1 by interacting electrostatically with the inner surface of the 
 
 
Figure 2.3: Proposed models of the copper transfer pathway and intracellular localization 
of ATP7B.  Atox1 can either receive copper directly from hCtr1 (red solid arrow) or from 
copper-bound GSH (red dashed arrow).  Atox1 transfers Cu(I) to ATP7B (black arrow).  In the 
presence of copper, ATP7B will traffic to the apical membrane for subsequent copper excretion.  
To reach the apical membrane, two distinct trafficking routes have been proposed:  ATP7B can 
either traffic to lysosomes (green solid arrows) or to basolateral endosomes (green dashed 
arrows) for subsequent excretion.     
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membrane bilayer (Flores and Unger, 2013) (Figure 2.3; red solid arrows).  This mechanism has 
been observed for CCS (copper chaperone for superoxide dismutase 1) (Pope et al., 2013), as 
CCS must interact with lipid bilayers before activating superoxide dismutase 1 (SOD1) (Pope et 
al., 2013).  Direct interaction between copper chaperones and the C-terminal copper-binding 
motif of hCtr1 would ensure an efficient mechanism of copper uptake and delivery in the cell.    
 
Intracellular copper levels are controlled by protein-protein interactions and copper-
dependent trafficking of ATP7B to different cell compartments.  The human copper chaperone 
Atox1 plays a major role in copper distribution to the TGN, delivering copper to ATP7B and 
ATP7A (Hamza et al., 1999).  Copper regulation of ATP7B is achieved by copper-induced 
trafficking (Figure 2.3).  Although some studies have demonstrated that ATP7B does not exhibit 
copper-dependent trafficking (Harada et al., 2010; 2000), the general consensus is that, under 
low or basal copper concentrations, ATP7B is localized to the TGN.  ATP7B transports copper 
from the cytoplasm into the lumen of the TGN for incorporation into various copper-dependent 
enzymes such as ceruloplasmin (CP), a major copper-carrying protein in the blood (Cater et al., 
2004; 2006; Hung et al., 1997; Schaefer et al., 1999).  An increase in copper concentration, 
however, triggers the movement of ATP7B from the TGN into cytoplasmic vesicles, which 
sequesters excess copper to be later removed by exocytosis at the apical canalicular membrane 
(Cater et al., 2006; Hung et al., 1997; Roelofsen et al., 2000).  This process is reversible, 
allowing ATP7B to be recycled back into the TGN upon copper concentration decrease.  Despite 
the observation of ATP7B copper-dependent trafficking to different cell compartments, the 
identity of the cytoplasmic vesicles and the trafficking route is still controversial.  A study 
demonstrated that ATP7B directly traffics to lysosomes, which leads to ATP7B-lysosome 
mediated exocytosis at the apical membrane in HepG2 cells (Polishchuk et al., 2014) (Figure 2.3; 
green solid arrows).  In contrast, two independent studies have more recently demonstrated that 
ATP7B reaches the apical membrane via basolateral endosomes (Lalioti et al., 2016; Nyasae et 
al., 2014) (Figure 2.3; green dashed arrows).  ATP7B is then transported with the endosomes by 
transcytosis to the apical membrane (Lalioti et al., 2016).  It is clear that ATP7B traffics to the 
apical membrane upon copper elevation, however, the identity of the ‘cytoplasmic vesicles’ is 
still uncertain.     
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 In response to copper elevation, the exposure of characteristic sequence motifs in ATP7B 
may trigger the binding of proteins involved in ATP7B trafficking.  Sequence differences in the 
N-terminal region of ATP7B and ATP7A may facilitate binding of different trafficking proteins.  
It has been demonstrated that the TGN retention signal at low copper and apical targeting signal 
at high copper resides in the F37AFDNVGYE45 (F37-E45) sequence (Braiterman et al., 2008), 
located in the first 63 amino acids of the N-terminal region (Guo, 2005).  These 63 amino acids 
in the N-terminal region of ATP7B are absent in ATP7A.   This may explain why ATP7A 
migrates to the basolateral membrane, while ATP7B trafficks to the apical membrane upon 
copper elevation in polarized cells (Lutsenko et al., 2007).  
2.2 Copper-transporting ATPase ATP7B 
2.2.1 Structural organization and mechanism of copper transport 
 ATP7A and ATP7B are P1B-type ATPases that use the energy of ATP hydrolysis to 
transport copper across the cell membrane.  ATP7A and ATP7B are large membrane proteins 
with a 56% sequence identity and a molecular weight of approximately 180 kDa and 165 kDa, 
respectively.  The structures for ATP7A or ATP7B have not been determined, but homology 
models from bacterial Cu+-ATPases (Gourdon et al., 2011) and other P-type ATPases 
(Toyoshima, et al., 2000; Apell, 2004) have provided structural and mechanistic insights into 
these transporters.   
 
ATP7A and ATP7B consist of eight transmembrane helices and four distinct cytosolic 
modules:  the N-terminal region, actuator domain (A-domain), ATP-binding domain (ATP-BD), 
which is composed of the phosphorylation (P-domain) and nucleotide-binding domain (N-
domain), and a small C-terminus (Figure 2.4A).  Except for P-domain, the structures for all the 
individual cytosolic domains in ATP7B have been determined.  The N-domain is composed of 
six-stranded antiparallel β-sheets with two α-helical hairpins on each side of the β sheet (Figure 
2.4B; green).  Although the N-domain of ATP7B lacks sequence similarity to other P-type 
ATPases, the overall fold of this domain is highly conserved (Dmitriev et al., 2006).  This 
demonstrates that the basic structural features of the domain have been conserved across 
evolution to perform the essential function of binding ATP.  The A-domain of both ATP7A and 
ATP7B is composed of seven antiparallel β-sheets and two helices (Figure 2.4B; magenta).  The 
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β-sheets form a double-stranded beta-alpha fold with two helices protruding outward (Banci et 
al., 2009b) (Figure 2.4B; magenta).   
  
 
Figure 2.4: Domain architecture of ATP7B.  (A) Homology model of ATP7B showing the 
metal-binding domains (orange), actuator domain (yellow), ATP-binding domain (P- and N-
domains; cyan), and the transmembrane helices (red) (Schushan et al., 2012). (B) Linear 
structure of ATP7B indicating domain boundaries and linker lengths between MBDs. (C) 
Solution structures of the nucleotide-binding (green) (Dmitriev et al., 2006) and actuator domain 
(magenta) (Banci et al., 2009b).  The highly conserved sequences involved in the catalytic cycle 
are labeled (blue).    
  
The crystal structure of Legionella pneumophila CopA Cu+-ATPase (LpCopA) provides 
mechanistic insights for copper binding in the transmembrane helices (Andersson et al., 2013; 
Gourdon et al., 2011).  The single metal-binding domain of LpCopA was not resolved in the 
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crystal structure because of weak electron density (Andersson et al., 2013; Gourdon et al., 2011).  
This suggests that the high flexibility of the N-terminal region of ATP7B may preclude X-ray 
structure determination.   
 
Similar to other P-type ATPases, ATP7B follows the Post-Albers catalytic cycle to 
transport copper ions across the cell membrane.  The Post-Albers catalytic cycle transitions 
between two distinct protein conformations, E1, which binds the metal with high-affinity, and 
E2, the low affinity state, which releases the ion across the membrane (Albers, 1967) (Figure 
2.5).  Copper(I) binds to the high affinity CPC copper-binding motif located in the sixth 
transmembrane helix (E1).  This triggers conformational changes in the cytoplasmic domains, 
allowing ATP to bind to the highly conserved SEHPL sequence in the N-domain (E1-ATP).  A 
transient phosphorylated intermediate is formed when the γ-phosphate of ATP is transferred to 
the aspartate residue of the DKTG motif in the P-domain (E1-ADP).  This phosphorylated 
intermediate is a key step in the catalytic cycle of all P-type ATPases.  Transient phosphorylation 
of the P-domain induces rotational movement of the A-domain, allowing the two domains to 
interact with each other (E1-ADP; black arrow).  These cytoplasmic domain movements reduce 
affinity of the copper-binding site in the CPC motif (E2P), which releases copper to the other 
side of the membrane.  Subsequently, the highly conserved TGE loop protruding from the 
surface of the A-domain (Banci et al., 2009b) interacts electrostatically with the DKTG motif in 
the P-domain (Sazinsky et al., 2006).  The TGE loop of the A-domain dephosphorylates the P-
domain, thereby resetting the catalytic cycle of ATP7B (E2) for the next round of copper transfer 
across the membrane.  Although copper binding to the highly conserved CPC motif is essential 
for copper translocation across the cell membrane, it is still unknown how copper reaches the 
binding site in the transmembrane region.   
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Figure 2.5: The Post-Albers catalytic cycle of ATP7B.  Copper binds to the high affinity-
binding site in the transmembrane region (E1).  ATP binds to the N-domain (E1-ATP).  The γ-
phosphate of ATP is transferred to the P-domain (E1-ADP).  Conformational changes in the 
cytoplasmic domains create a low-affinity state in the transmembrane region (E1-ADP; black 
arrows).  Copper is released to the other side of the membrane (E2P).  A-domain 
dephosphorylates the γ-phosphate attached to the P-domain, resetting the catalytic cycle (E2).    
 
 
	 		 	
	 11		
2.2.2 Role of the metal-binding domains 
 The cytosolic metal-binding domains are a characteristic feature of heavy-metal 
transporting ATPases.  The structures of individual MBDs in the N-terminal region are highly 
conserved, but the number of MBDs varies from one or two in bacteria to six in humans.  This 
may suggest a more complex regulatory function in higher order species.  Each MBD is 
approximately 70 amino acids long, with a ferredoxin-like fold (βαββαβ), containing one copy 
of the signature copper-binding motif, GMXCXXC.  Using biochemical (Lutsenko et al., 1997) 
and biophysical techniques (DiDonato et al., 2000; Wernimont, 2003), it is well established that 
the MBDs in ATP7B bind copper in the +1 oxidation state.  Copper(I) is coordinated between 
the two cysteine residues in a distorted linear geometry (DiDonato et al., 2000; Ralle et al., 
2004).  The structures of the individual domains of ATP7B in the apo- and metal-bound forms 
have been solved (Achila et al., 2006; Banci et al., 2008; Dolgova et al., 2013; Fatemi et al., 
2010). In the present work, we have solved the structure of MBD1 using NMR spectroscopy 
(PDB ID: 2N7Y) (Figure 2.6). 
 
Figure 2.6: The solution structures of all of the metal-binding domains of ATP7B.   
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The structures of the individual MBDs have been determined, but the arrangement of the 
individual MBDs within the context of all six MBDs is not well characterized.  Although the 
domain structures are similar, copper chaperone Atox1 preferentially transfers Cu(I) to MBD2 in 
the context of full-length MBD1-6 (Walker, 2004).  Since Cu(I) coordination and affinity are all 
similar among the MBDs, the preferential transfer of copper to MBD2 may be caused by 
differences in the amino acid composition on the contact surface of MBD2 and Atox1.  
Electrostatic interactions between a positively charged patch on Atox1 and a negative charged 
surface on MBD2 recognizes and correctly orients the two domains for copper transfer (Walker, 
2004).  Crystal structures of dimeric Atox1 bound to Cu(I), Hg(II), and Cd(II) ions at the CxxC 
motif show different ligand coordination numbers (Boal and Rosenzweig, 2009a).  These 
structures provide models that represent intermediates in the copper transfer mechanism.  X-ray 
absorption spectroscopy demonstrates that all of the MBDs bind Cu(I) between two sulfur atoms 
(DiDonato et al., 2000; Ralle et al., 2004).  Atox1 binds Cu(I) between two sulfur atoms of the 
cysteine residues and a possible third exogenous sulfur ligand (Ralle et al., 2004).  Ligand-
exchange of the cysteine side chains between Atox1 and the MBDs is proposed to be the primary 
mechanism for inter-domain copper transfer (Figure 2.7).  When Atox1-Cu docks to the MBD, 
the thiol side-chain from the cysteine residue of the MBD donates the third ligand to Atox1-Cu 
(Figure 2.7B).  The N-terminal cysteine residue of the MBD (C18) contributes the third thiol 
ligand to Atox1-Cu.  Once the heterodimer is stabilized by the third ligand, the sulfur bond 
breaks between Cu(I) and C15 from Atox1 (Figure 2.7C).  A sulfur bond is subsequently formed 
between the C-terminal cysteine residue of the MBD (C21) and Cu(I) (Figure 2.7C).  Finally, 
Cu(I) is coordinated between the two cysteine side-chains in the MBD (Figure 2.7D).   
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Figure 2.7: The ligand-exchange mechanism for inter-domain copper transfer.    
 
 Biochemical studies using site-directed mutagenesis and complementation analysis of 
various MBD constructs suggest a functional difference between the six MBDs in ATP7B, 
despite structural similarities between all MBDs.  Amino acid sequence analysis has revealed an 
unusually long linker between MBD4 and MBD5, suggesting two distinct functional groups, one 
comprising MBD1-4 and the other MBD5-6.  Mutational studies have demonstrated that MBD5 
or MBD6, the domains closest to the transmembrane helices, are critical for the transport of 
copper and trafficking of ATP7B (Cater et al., 2004).  The first three MBDs were not able to 
functionally replace MBD4-6, which confirms that the individual MBDs are not functionally 
equivalent (Cater et al., 2004).  MBD1-4 have been suggested to regulate copper transport and 
trafficking of ATP7B by affecting the accessibility of copper to MBD5 and MBD6 (Huster, 
2003).  This copper accessibility could be regulated by the interaction of the N-terminal region 
with ATP-BD (Tsivkovskii et al., 2000).  Copper binding to the MBDs decreased the domain-
domain interaction with ATP-BD (Tsivkovskii et al., 2000).  ATP-BD subsequently binds ATP 
and initiates the copper transport cycle (Tsivkovskii et al., 2000).  Caution must be taken, 
however, when examining the function of MBDs using MBD deletion constructs, as the absence 
of specific individual domains may affect the overall fold and function of the entire N-terminal 
region.   
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 Although extensive functional and structural work has been done with the individual 
MBDs, the conformation and dynamics of the N-terminal region containing all MBDs are not 
well characterized.  NMR studies using various deletion constructs have also suggested extensive 
flexibility between the MBDs (Achila et al., 2006; Fatemi et al., 2010).  This dynamic mobility 
may be important for the function of the N-terminal region by facilitating domain-domain 
interactions and promoting copper transfer to MBD5 or MBD6.  The sharp resonances in the 1H- 
15N HSQC spectrum of MBD1-6 is indicative of a high degree of independent tumbling for the 
MBDs, suggesting that MBD1-6 has a “beads-on-a-string” conformation (Banci et al., 2009a; 
Fatemi et al., 2010). However, biochemical studies show that mutations in MBD2 or MBD3 
affect copper binding to other MBDs (LeShane et al., 2010).  This suggests that inter-domain 
interactions are important for the regulation of copper transport and trafficking activity of 
ATP7B (LeShane et al., 2010).  Thus, one of our goals was to identify that transient interactions 
between a specific group of MBDs provide a mechanism for the regulation of ATP7B copper 
transport and trafficking activity.   
 
2.2.3 Menkes and Wilson disease  
 Menkes disease (MNKD) is an X-linked recessive disorder caused by mutations in the 
ATP7A gene.  As dietary copper is absorbed, it is transported into the intestinal cells through the 
apical membrane by hCtr1.  ATP7A is localized to the basolateral membrane of intestinal cells 
and transports copper to the portal blood circulation (Peña et al., 1999).  Deleterious mutations in 
the ATP7A gene inactivate the copper transporter (Figure 2.8).  This results in copper 
accumulation in the enterocyte, which leads to a copper deficiency to peripheral tissues.  The 
lack of copper in the blood renders important copper-dependent enzymes non-functional.  For 
example, peptidylglycine α-amidating monoxygenase (PAM) requires copper as a cofactor to 
catalyze the conversion of neuropeptides into the active α-amidating peptide form, while 
tyrosinase requires copper for proper development of skin pigmentation (Lutsenko et al., 2007).  
Abnormal skin pigmentation and connective tissue disorders are common symptoms for MNKD 
patients.  Disease symptoms present from two to three months of age and, if left untreated, 
infantile neurological problems and death occur very quickly (Kaler, 2011).  Currently, there is 
no effective treatment option for MNKD, but lifelong subcutaneous and intramuscular copper-
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histidine injections have shown to delay severe neurodegeneration and may enhance survival in 
infants (Kaler, 2011).      
 
Figure 2.8: Copper distribution in the body of patients with Menkes disease.  Dietary copper 
(yellow spheres) is absorbed in the small intestine.  Non-functional ATP7A blocks copper 
transport into the blood circulation, resulting in copper accumulation in the enterocyte.  This 
leads to a copper-deficiency to peripheral tissues.  If residual copper is present in the 
bloodstream, it cannot be transported into tissues that express ATP7A such as the brain, heart, 
and lungs.     
           
Wilson disease (WD) is an autosomal recessive liver disorder caused by mutations in the ATP7B 
gene.  The lack of copper excretion into bile and defective copper transport into the peripheral 
blood circulation results in severe copper toxicity (Figure 2.9).  The liver and kidneys are the 
organs that are primarily affected by copper toxicity (Lutsenko et al., 2007). There are a 
multitude of disease-causing mutations that affect different regions of ATP7B, but the most 
common mutations are located within the nucleotide-binding domain (N-domain) (Kenney and 
Cox, 2007) (Figure 2.10). In particular, the H1069Q is the most common mutation, found in 
approximately 38% of WD patients (Shah et al., 1997).  Using solution NMR, the H1069Q 
mutation has been demonstrated to disrupt tight binding of ATP (Dmitriev et al., 2006).  
Depending on the mutation, there are other mechanisms that can inactivate ATP7B activity, such 
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as decreased protein stability (Braiterman et al., 2011), mislocalization (Gupta et al., 2011), and 
protein truncation (Braiterman et al., 2011).  If left untreated, this toxic accumulation results in 
severe liver disease and eventual death (Schilsky, 2002).  Currently, copper chelating agents and  
zinc therapy are effective treatment options for Wilson disease (Schilsky, 2002).  Copper 
chelating agents such as D-penicillamine, trientine, and tetrathiomolybdate mobilize copper and 
facilitate its excretion, whereas zinc induces the synthesis of metallothioneins, which sequester 
copper (Schilsky, 2002).   
 
 
Figure 2.9: Copper distribution in the body of patients with Wilson disease.  Dietary copper 
(yellow spheres) is absorbed in the small intestine.  ATP7A exports copper from the enterocyte 
into the blood circulation.  Copper-bound to serum proteins are transported primarily to the liver 
and kidneys.  Non-functional ATP7B blocks copper excretion into the bile and prevents copper-
incorporation into copper-dependent enzymes such as ceruloplasmin and albumin for peripheral 
blood circulation.           
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Figure 2.10: Domain distribution of Wilson disease mutations.     
 
2.3 Cisplatin and its mechanism of action 
 Although ATP7B is involved in maintaining copper homeostasis in the body, 
overexpression of ATP7B is associated with tumor resistance to cisplatin during chemotherapy.  
Cisplatin (cis-diamminedichloroplatinum, DDP) is a widely used drug for treating testicular, 
ovarian, stomach, and bladder cancers.  It is an effective cancer treatment option, but intrinsic 
and acquired resistance to DDP are severe problems in cancer chemotherapy.  Although the 
mechanisms of DDP resistance are diverse, there is a strong correlation between DDP resistance 
and the amount of ATP7B in the cell.  To combat DDP resistance, next generation DDP analogs, 
which include carboplatin and oxaliplatin, have been developed  (Figure 2.11).  Understanding 
the mechanisms of DDP resistance will allow strategies to be developed to increase the 
effectiveness of DDP against specific cancer cells while reducing cell toxicity.       
 
Figure 2.11: Chemical structure of platinum-based drugs.  (A) Cisplatin.  (B) Carboplatin.  
(C) Oxaliplatin.   
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Cisplatin is a neutral, planar Pt(II) complex with two chloride and two ammine ligands 
oriented in cis-configuration (Jamieson and Lippard, 1999).  When DDP is intravenously 
injected into the bloodstream, high chloride concentrations (100 mM) suppress aquation and 
DDP remains in a neutral state (Figure 2.12).  DDP was previously thought to enter the cell by 
passive diffusion (Binks and Dobrota, 1990).  More recent evidence, however, demonstrates that 
DDP enters the cell by passive transport through hCtr1 (Ishida et al., 2002).  Upon entry into the 
cell, diminished chloride concentrations (20 mM) quickly promote aquation of the first Cl- 
ligand.  This creates a positively charged intermediate that can form mono-functional platinum 
adducts with DNA and proteins (Figure 2.12; purple arrow).  Bi-functional platinum adducts 
with DNA and proteins can also be formed when aquation of the second Cl- ligand is induced 
(Figure 2.12; green arrow).    
 
Figure 2.12: Cisplatin reaction chemistry in the cell.  When cisplatin enters the cell, it forms a 
positively charged intermediate that can readily bind to DNA (red arrow) and other cellular 
components (purple arrow).  When cisplatin loses its second chloride ligand, bi-functional 
adducts can be formed with other proteins and RNA (green arrow).              
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DDP functions by primarily reacting with DNA in the cell nucleus (Figure 2.12; red 
arrows).  DDP binds at the N-7 position of guanine, forming 2-d(GpG) intrastrand crosslinks, 
which is the most common cisplatin-DNA adduct (Figure 2.13).  However, other intra- and inter-
strand DNA crosslinks are also present (Fichtinger-Schepman and Van der Veer, 1985).  Based 
on the structures of different cisplatin-DNA adducts, cisplatin binding unwinds and destabilizes 
the DNA, which creates various DNA distortions near the platination site (Cohen et al., 1979; 
Coste et al., 1999; Gelasco and Lippard, 1998).  These crosslinks prevent DNA transcription and 
replication, which is particularly effective against rapidly dividing cancer cells.  The structural 
distortions caused by cisplatin binding signals DNA damage and eventually induces apoptosis 
through various biochemical reactions (Bellacosa, 2001; Nehmé et al., 1997).  Although cisplatin 
is very effective against certain types of cancers, intrinsic and acquired resistance limits its 
effectiveness.   
 
Figure 2.13: Cisplatin binding to DNA forms 1,2-d(GpG) intrastrand crosslinks.    
 
2.4 Copper-transport proteins contribute to the multifactorial mechanism of cisplatin 
resistance 
Cisplatin binds to and reacts with different cellular components, giving rise to multiple 
pathways of cisplatin resistance in the cell.  There are four broad categories for cisplatin 
resistance, which include reduced cisplatin uptake, drug detoxification in the cytosol, accelerated 
efflux of cisplatin out of the cell, and increased DNA repair (Figure 2.14).   
 
DNA is the primary target for cisplatin binding (Figure 2.14; blue arrow).  Effective 
DNA repair mechanisms are required for preventing the formation of DNA-platinum adducts.  
The nucleotide excision repair (NER) system is primarily responsible for repairing DNA lesions 
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and has been shown to be associated with cisplatin resistance (Jung and Lippard, 2007).  At a 
platinum lesion, stalled RNA polymerase II acts as a signal to recruit different NER proteins.  
After a complex of DNA repair proteins are formed, helicases unwind the double-stranded DNA, 
and an endonuclease excises 24-32 nucleotides in which the platinum lesion is located (Jung and 
Lippard, 2007).  It was demonstrated that xeroderma pigmentosum cells, which have 
components defective in NER is five to ten times more sensitive to cisplatin than normal 
fibroblast cells (Furuta et al., 2002).  Additionally, a two- to three-fold increase in the mRNA 
levels of xeroderma pigmentosm complementation group A (XPA) was associated with cisplatin 
resistance in ovarian cancer cell lines (States and Reed, 1996).  XPA is a key component in the 
NER pathway that recognizes DNA lesions (States and Reed, 1996).   
 
Elevated levels of intracellular glutathione have also been associated with cisplatin 
resistance (Figure 2.14; orange arrow).  Binding of cisplatin to gluthathione forms Pt-(GS)2 
complexes (Ishikawa and Ali-Osman, 1993).  These complexes prevent platinum from reaching 
the nucleus and reacting with DNA.  Additionally, Pt-(GS)2 can also be actively transported out 
of the cell by the GS-X pump (Kurokawa et al., 1995).  A two-fold increase in the concentration 
of GSH inside the cell increases the GS-X pump activity, resulting in decreased cisplatin 
accumulation (Kurokawa et al., 1995).   
 
Different cisplatin resistance mechanisms mediated by various copper transport proteins 
have been proposed.  The passive copper transporter, hCtr1, was demonstrated to mediate the 
uptake of cisplatin into the cell (Figure 2.14; green arrow) (Ishida et al., 2002).  By deleting the 
CTR1 gene in both yeast and mouse cell lines, a decrease in cisplatin accumulation was observed 
(Ishida et al., 2002).  This decreased cisplatin-DNA adduct formation and increased cisplatin 
resistance.  However, the precise mechanism for cisplatin uptake by hCtr1 is still unknown.  
Since cisplatin has a larger diameter than Cu(I), it may be not transported directly through the 
hCtr1 channel.  Rather, cisplatin may bind to extracellular motifs at the plasma membrane and 
trigger hCtr1 internalization by macropinocytosis (Figure 2.14; pink arrow) (Holzer and Howell, 
2006).  The distinct copper and cisplatin uptake mechanisms of hCtr1 have been supported by 
fluorescence resonance energy transfer (FRET) experiments (Sinani et al., 2007).  It was 
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demonstrated that specific Ctr1 mutants defective in copper transport enhanced cisplatin 
accumulation, whereas a copper transport active mutant did not accumulate cisplatin.              
 
The copper chaperone Atox1 was demonstrated to mediate cisplatin resistance using 
different mechanisms.  The deletion of Atox1 decreased cisplatin influx by preventing 
macropinocytosis and internationalization of hCtr1 (Safaei et al., 2009).  It was suggested that 
the direct interaction of Atox1 with the C-terminal region of hCtr1 facilitates the 
polyubiquitination of hCtr1, resulting in the degradation of the copper transporter (Safaei et al., 
2009).  Therefore, reduced Atox1 expression levels in specific cancer cells may lead to cisplatin 
resistance.  Additionally, structural studies have demonstrated that cisplatin binds to the CxxC 
copper-binding motif in Atox1 (Boal and Rosenzweig, 2009b; Palm et al., 2011).  Cisplatin-
induced unfolding of Atox1 was observed in vitro at a high cisplatin to protein ratio, which is 
unlikely to exist in the cell (Palm et al., 2011).  The unfolding of Atox1 caused by cisplatin 
binding would stop cisplatin transport in the cytoplasm and prevent platinum from entering the 
nucleus to exert its toxic effect.  Lastly, our studies have demonstrated that cisplatin can hijack 
the Atox1 copper transport pathway (Dolgova et al., 2013).  Similarly to copper, Atox1 can bind 
and transfer cisplatin to the MBDs of ATP7B (Figure 2.14; purple arrow) (Dolgova et al., 2013).  
This Atox1-ATP7B interaction may be an important pathway for cisplatin detoxification in the 
cell.              
 
Copper transporter ATP7B has also been associated with tumor resistance to cisplatin 
(Figure 2.14; red arrow).  It was demonstrated that cells with higher expression levels of ATP7B 
were resistant to cisplatin chemotherapy (Komatsu et al., 2000; Nakayama et al., 2002; 2004).  
The mRNA levels of ATP7B were also elevated in oral squamous carcinoma resistant cell lines 
(Yoshizawa et al., 2007).  In the same cell line, there was no correlation between cisplatin 
resistance and the expression levels of other copper proteins (Yoshizawa et al., 2007).  
Interestingly, the silencing of ATP7B using siRNA increased cisplatin cytotoxicity by 10-fold in 
resistant cells (Yoshizawa et al., 2007).  The active transport of platinum across the cell 
membrane by ATP7B has been suggested to be the primary mechanism of cisplatin resistance 
(Safaei et al., 2007).  However, low transport rates at physiological pH and high substrate 
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specificity of ATP7B for copper suggests that active extrusion is unlikely to be a major 
mechanism of cisplatin resistance in vivo.   
 
An alternative mechanism to active transport involves sequestering cisplatin in the metal-
binding domains of ATP7B.  A previous study in our lab demonstrated that cisplatin is 
sequestered at the metal-binding domains (Dolgova et al., 2009).  Protein expression of the first 
four metal-binding domains (MBD1-4) protected E. coli cells from the toxic effects of cisplatin 
(Dolgova et al., 2009).  MBD1-4 was entirely cytosolic demonstrating that active transport is not 
required for cisplatin resistance associated with ATP7B.  One of our goals in this thesis was to 
investigate the mechanism of cisplatin detoxification by the metal-binding domains of ATP7B.       
 
Figure 2.14: Proposed mechanisms of cisplatin resistance.  Cisplatin enters the cell through 
hCtr1 either by facilitated diffusion through the transmembrane pore (green arrow) or by 
macropinocytosis (pink arrows).  When cisplatin enters the cytosol, it can bind to different 
acceptors.  Cisplatin binding to glutathione forms Pt-(GS)2 complexes that can be excreted out of 
the cell by the GS-X pump (orange arrows).  Atox1 also binds cisplatin (purple arrow) and 
delivers platinum to ATP7A and ATP7B.  A fraction of cisplatin escapes detoxification and 
reaches DNA in the nucleus (blue arrow).   
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2.5 Nuclear magnetic resonance spectroscopy techniques to study protein structure and 
dynamics of metal-binding domains 
2.5.1 Heteronuclear Single Quantum Coherence (HSQC) 
Nuclear magnetic resonance (NMR) spectroscopy is a powerful method for studying the 
structure and dynamics of proteins.  Advancements in magnet design, pulse sequences, isotopic 
labeling, and data processing computer software packages make it more efficient to solve the 
structures of smaller proteins, such as the metal-binding domains of ATP7B, by NMR.  NMR is 
also an effective method for determining the metal-binding sites and contact surfaces of multi-
domain proteins by chemical shift perturbation analysis.  More importantly, however, NMR is 
the most powerful method for studying protein dynamics.  Protein dynamics have provided 
functional insights into the highly mobile N-terminal region of ATP7B.  Understanding the 
conformation of the N-terminal region has helped us identify a specific group of MBDs that 
function in the regulation of ATP7B copper transport and trafficking activity.   
 
NMR relies on the magnetic properties of individual nuclei for studying and solving 
three-dimensional protein structures at atomic resolution. Spin is a quantum property that is 
related to the intrinsic angular momentum of a nucleus and is described by the quantum number 
I.  However, in order for a nucleus to be NMR detectable, it must have a non-zero value of I.  
Typically, the nuclei used in protein structure determination have a spin of ½.  These isotopes 
include 1H, 15N, and 13C.  Since the natural abundance of 15N and 13C is low, isotopic enrichment 
is typically used for protein NMR studies.   
 
Similar to other forms of spectroscopy, NMR relies on a transition between two different 
energy states, a ground and an excited state.  In an external magnetic field (B0), the magnetic 
moment of a nucleus (I = ½) will either orient parallel or anti-parallel to B0, which corresponds 
to a lower or higher energy state, respectively (Figure 2.15).  The spin population difference 
between the energy states is given by the Boltzmann distribution.  A slight excess of spins will 
be oriented parallel to the B0 field, which creates a net magnetization (Mo) vector along the B0 
field (Figure 2.15A).  A radiofrequency (RF) pulse is applied to induce the transition of the 
nuclei from the ground to higher energy states.  When the M0 vector rotates from the z-axis onto 
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the x-y plane, the net magnetization vector gives rise to an observable NMR signal (Figure 
2.15B).  The free induction decay (FID) is the time-dependent NMR signal that reflects the 
resonance frequency of a nucleus (Figure 2.15C).     
 
Figure 2.15: The effect of an external magnetic field on an ensemble of spins.  (A) At 
equilibrium, there is a slight excess of spins in the low energy state, causing the magnetization 
vector to orient parallel with the B0 field.  (B) An RF pulse rotates the spins onto the x-y plane.  
(C) After the RF pulse is applied, the spins precess around the x-y plane in a time-dependent 
manner.  The frequency of an individual nuclei precessing around the x-y plane is recorded as an 
FID.         
 
The absorption of energy by a particular nucleus is dependent on a characteristic 
precession frequency, also known as the Larmor frequency:    
ω0 = -γB0,             (2.4) 
where ω0 is the resonance frequency of a nucleus, γ is the gyromagnetic ratio, and B0 is the 
strength of the external magnetic field.  The gyromagnetic ratio (γ) is defined by the ratio of the 
magnetic moment of the nucleus to its angular momentum.  This reflects the strength of the 
NMR signal for a particular type of nucleus.  Nuclei in proteins are subject to different electron 
density configurations, which change the effective magnetic field the nucleus experiences in the 
	 		 	
	 25		
external magnetic field.  This changes the resonance frequency for each chemically distinct 
nucleus: 
ω = -γ(B0 – Bi),                  (2.5) 
where ω is the specific resonance frequency of a nucleus, B0 is the strength of the external 
magnetic field, and Bi is the change in magnetic field.  This difference in resonance frequency 
between the nuclei is called the chemical shift (δ).  Chemical shift is measured in parts per 
million (ppm) and compares the resonance frequency of a nucleus (υsample) to the resonance 
frequency of a well-established standard (υref):   
δ (ppm) =υsample – υref x 106         (2.6) 
          υref 
The chemical shift scale is independent of the external magnetic field, which allows direct 
comparison between spectra recorded at different magnetic field strengths.  
 
The most routinely used experiment in protein NMR is the 2D 1H, 15N-heteronuclear 
single quantum coherence (HSQC).  The 2D 1H-15N HSQC spectrum is often considered the 
NMR fingerprint of a protein because each spectrum shows the signal from a backbone amide 
group, or a side chain group of glutamine, asparagine, arginine, or tryptophan in the protein 
sequence (Figure 2.16).  Protons have very high sensitivity because of the much larger 
gyromagnetic ratio than 15N.  Therefore, to maximize the sensitivity of the 15N signal, 
magnetization is transferred from 1H to 15N by an NMR technique called polarization transfer 
(Morris and Freeman, 1979).  Magnetization is subsequently transferred from 15N back to 1H to 
maximize signal detection sensitivity.  The 2D 15N-HSQC spectrum is often suitable for smaller 
proteins, but the resolution is often not sufficient for larger proteins (>25 kDa).   
 
The transverse relaxation optimized spectroscopy (TROSY) technique is often used for 
recording the spectra of larger proteins.  The information content is identical to the HSQC, 
except that TROSY has improved spectral resolution.  In a backbone amide group, the hydrogen 
and nitrogen atoms are J-coupled.  J-coupling is the interaction of two nuclei mediated through 
electrons in the chemical bonds.  Nuclei that are J-coupled should produce four peaks in the 
HSQC spectrum (Figure 2.17A).  In a typical 1H, 15N-HSQC spectrum (Figure 2.16), decoupling 
is applied during detection, which merges four peaks into one single peak (Figure 2.17B).  The 
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TROSY technique specifically selects for the multiplet component with the narrowest linewidth 
(Figure 2.17C).  As a result, the TROSY technique is particularly advantageous for large proteins 
with significant peak overlap.                 
 
Figure 2.16:  1H, 15N-HSQC spectrum of MBD1.  Each peak in the spectrum corresponds to a 
unique backbone amide group or a side chain amide group of glutamine, asparagine, arginine, or 
tryptophan in the protein sequence (blue square).       
 
 
 
Figure 2.17: The difference between an HSQC or TROSY experiment on an NMR signal.  
1H, 15N spectra for one residue in a (A) non-decoupled HSQC, (B) decoupled HSQC and (C) 
TROSY.   
	 		 	
	 27		
2.5.2 NMR relaxation 
Relaxation is a fundamental process where the excited nuclear spins return to their 
equilibrium state.  NMR relaxation is induced by the interaction and fluctuation of local 
magnetic fields.  Relaxation is used in different aspects of NMR spectroscopy such as transfer of 
magnetization to nearby atoms and protein dynamics.  The two mechanisms of NMR relaxation 
are longitudinal (R1) and transverse (R2) relaxation.  The relaxation rates are the inverse of the 
relaxation times according to the equations:  
R1 = 1/T1 and R2 = 1/T2.         (2.7) 
Longitudinal (spin-lattice) relaxation releases energy to the external environment, causing 
the population of the nuclei in the excited state to return back to equilibrium.  This relaxation 
process only affects the z-axis (Mz) (Figure 2.18A). Transverse (spin-spin) relaxation is a process 
that is caused by the magnetic fields of interacting spins.  Immediately after excitation, the spins 
are precessing coherently in the x-y plane (Figure 2.17B).  Over time, coherence is lost and the 
spins become dephased (Figure 2.18B; blue arrows).  Since longitudinal relaxation restores 
magnetization on the z-axis (Mz) and transverse relaxation affects the magnetization vector in the 
x-y plane (Mxy), these relaxation mechanisms are treated as independent processes.  The Bloch 
equations calculate the net magnetization of the nuclear spins under the influence of relaxation: 
dMz = M0 – Mz         (2.8) 
 dt      T1 
dMx =  – Mx          (2.9) 
 dt      T2 
dMy =  – My         (2.10) 
 dt      T2 
 
 Experimentally, T1 determines the time required before a RF pulse can be applied to the 
nuclei again, whereas T2 determines the time it takes for the signal to decay.          
	 		 	
	 28		
 
Figure 2.18:  The effect of relaxation on the magnetization vectors after an RF pulse. (A) 
Longitudinal and (B) transverse relaxation of magnetization vectors after a 90° RF pulse.    
 
 
 
 
Figure 2.19: Time-dependent net magnetization for longitudinal (left) and transverse 
relaxation (right).   
 
As molecules become larger, the transverse relaxation rate increases.  After excitation, 
the amplitude of the FID is at a maximum because the nuclei are precessing coherently in the x-y 
plane.  Larger proteins, however, will decay back to their equilibrium at a much a faster rate than 
smaller proteins (Figure 2.20).  A faster transverse relaxation rate means there is less time to 
detect the signal, causing peaks in the spectra to broaden out and disappear.  Therefore, 
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transverse relaxation determines the linewidth of the NMR signal and is the primary determinant 
of spectral resolution.   
 
Figure 2.20:  The effect of protein size on the decay rate of the FID and the resulting 
linewidth of a peak.  Smaller proteins have slower decaying FIDs, which lead to narrow 
linewidths in the spectrum.  The FIDs of larger proteins decay quickly, resulting in a broad peak.   
 
NMR relaxation is dependent on molecular motion and, thus, is an accurate indicator of 
protein dynamics.  Protein dynamics are measured from R1, R2, and 1H, 15N heteronuclear NOE 
experiments (Kay et al., 1989).  The relaxation rates are obtained by fitting the exponential R1 
and R2 decay curves from the peak volumes or intensities of the backbone amide groups, in a 
series of 2D 1H-15N HSQC spectra recorded with increasing relaxation delays.  Since the 1H, 15N 
heteronuclear NOE has a defined distance between the two atoms; increased motion about the 
NH bond vector is measured by a decreased NOE intensity.  By measuring the R1, R2, and 
heteronuclear NOE values of the backbone amide groups, the correlation time (τc) of the protein 
can be calculated (Kay et al., 1989).  This represents the overall tumbling of the molecule and the 
calculated value is the time it takes the molecule to rotate one radian in solution.   
	 		 	
	 30		
2.5.3 Backbone and side-chain chemical shift assignments 
 Three-dimensional experiments are commonly used for assigning the backbone residues 
of proteins.  These experiments require isotopic labeling with 15N and 13C.  A 3D experiment 
spreads the NMR signal observed from a 2D plane (Figure 2.21A) into a 3D dataset with three 
correlated chemical shifts (Figure 2.21B).  Separating the correlated chemical shift of 1H, 15N, 
and 13C for a specific amino acid residue reduces spectral overlap and backbone assignment 
ambiguity.  In many common backbone assignment experiments, magnetization is transferred to 
different backbone atoms that are connected through one or several covalent bonds (Figure 2.22).   
 
Figure 2.21: Visualization of a (A) 2D plane into a (B) 3D dataset for chemical shift 
assignments.   
 
Amino acid residues are identified by connecting different spin systems from various 
backbone assignment experiments.  Inter-residue and intra-residue connectivities can be 
distinguished by using these pairs of experiments:  HNCO/HN(CA)CO, 
HNCACB/HN(CO)CACB, and HNCA/HN(CO)CA (Figure 2.22) (Gardner and Kay, 1998).  For 
example, the HNCA experiment connects the backbone amide group to the alpha carbons of both 
the same (Cαi) and the previous (Cαi-1) residue in the amino acid sequence (Figure 2.23B).  
Using the HNCA experiment, as an example, sequential residues are assigned by connecting the 
Cαi-1 of the current residue (K50) to the Cαi of the preceding residue (V49).  The HNCO 
experiment contains carbonyl carbon chemical shifts for only the previous (i-1) residue and the 
HN(CA)CO experiment contains carbonyl carbon chemical shifts both the i and i-1 residue.  The 
HN(CO)CACB experiment contains α- and β-carbons for i-1 residue and the HNCACB contains 
alpha and beta carbons for both the i and i-1 residues.   
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Figure 2.22: Magnetization transfer scheme for the (A) backbone and (B) side-chain 
assignment experiments.  All the backbone 3D experiments used in our work start with 
magnetization transfer from the backbone hydrogen to nitrogen and then to the desired 
heteronucleus.  Magnetization is subsequently transferred back to hydrogen along the same 
pathway for detection.  H(CCO)NH and CC(CO)NH starts with magnetization transfer from the 
side-chain protons to the attached carbons, and then on to the nitrogen and backbone hydrogen.  
1H, 15N-TOCSY starts with magnetization transfer between the hydrogen atoms.  Magnetization 
is subsequently transferred to nitrogen then back to the hydrogen atoms for detection.  For the 
side-chain experiments, the carbon atom (yellow) indicates connectivities that go beyond Cβ.      
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Figure 2.23:  The sequential assignment of residues using the 3D HNCA experiment.  (A) 
2D 1H, 15N-HSQC plane of MBD1.  (B) 1H, 13Cα-2D strips for the residues circled in the 2D 
HSQC in (A).  The inter- and intra-residue Cα are shown as crosspeaks in the 2D strips.  The 
inter-residue Cα has weaker peak intensity than the intra-residue Cα.    
 
 Three-dimensional side-chain experiments are used to assign the side-chain hydrogen and 
carbon chemical shifts of the corresponding amino acids (Figure 2.22B).  Based on the number 
and values of distinct hydrogen and carbon chemical shifts for each amino acid residue, side-
chain assignment experiments can also be used as a tool to verify the sequential backbone 
assignment.  The standard side-chain assignment experiments are CC(CO)NH, H(CCO)NH, and 
15N-TOCSY-HSQC (Gardner and Kay, 1998).  The CC(CO)NH experiment identifies the side-
chain carbon chemical shifts of the previous residue (i-1), whereas the H(CCO)NH experiment 
identifies the side-chain hydrogen chemical shifts of the previous residue (i-1).  The 15N-
TOCSY-HSQC experiment identifies the side-chain hydrogen chemical shifts of the current 
residue and is used in conjunction with the H(CCO)NH experiment.   
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2.5.4 Chemical shift perturbation mapping 
 Since chemical shifts are highly sensitive probes of the chemical environment, the ligand-
binding site can be determined by mapping the chemical shift changes of the assigned residues in 
a series of 2D 15N-HSQC or TROSY spectra.  Chemical shift perturbation (CSP) analysis 
requires the addition of an unlabeled ligand to an isotopically labeled 15N protein, or vice versa.  
The unlabeled ligand is titrated at increasing ratios until ligand binding to the 15N protein is 
complete (Figure 2.24).  The combined chemical shift changes are commonly calculated 
according to the following equation: 
    Δδcombined = [(Δδ2H + Δδ2N/25)/2]1/2,       (2.11) 
 
where ΔδNH and ΔδN are the chemical shift changes of the amide proton and nitrogen, 
respectively.  A scaling factor for the 15N chemical shift was applied to account for the 
differences in spectral widths between 1H and 15N resonances (Garrett et al., 1997; Grzesiek et 
al., 1996; Byerly et al., 2002).  CSP can reveal important structural information about the binding 
surface and possible conformational changes within the protein.    
 
NMR spectroscopy can detect ligand- or protein-protein interactions ranging from the 
millimolar to sub-nanomolar affinities.  The ligand-binding affinity can be estimated by 
analyzing the chemical exchange regime the affected residues undergo.  Chemical exchange is a 
dynamic process where an individual nucleus interconverts between two distinct chemical 
environments (Göbl et al., 2014).  Residues can undergo three different types of exchange 
processes: fast, intermediate, and slow exchange.  Fast exchange is associated with weak 
binding, usually in the millimolar range.  In the fast exchange regime, only one peak is observed, 
and its coordinate is given by the weighted average of the chemical shifts of the free and ligand-
bound state (Figure 2.24A).  Intermediate exchange is usually correlated with micromolar 
affinities and is observed by the broadening of peaks and sometimes complete signal 
disappearance (Figure 2.24B).    Slow exchange is correlated with tight binding and is 
manifested by two distinct peak signals corresponding to the free and bound states (Figure 
2.24C).  
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Figure 2.24: The chemical shift progression of one residue based on the different chemical 
exchange regimes.  The 15N-labeled protein goes from a free (blue circle) to a bound state (red 
circle).  (A) In the fast exchange regime, peaks gradually shift to a new location as ligand is 
added.  (B) In the intermediate exchange regime, peaks gradually shift to a new location and lose 
peak intensity as ligand is added.  (C) In the slow exchange regime, the free and bound states are 
both observed until complete binding is reached.   
 
 
 2.5.5 NMR structure calculation 
 NMR structure determination involves using a set of experimentally derived restraints to 
calculate an ensemble of energy-minimized structures (Figure 2.25).  The initial step for all 
NMR structure calculations is to identify the chemical shifts for as many chemically distinct 1H, 
15N, and 13C nuclei as possible.  This is accomplished by assigning the amino acid residues 
through sequential backbone and side-chain experiments (Figure 2.22).  Chemical shifts values 
are often correlated with protein secondary structure (Wishart et al., 1992), because each type of 
secondary structure has distinct ranges of φ and ψ dihedral backbone angles, as seen in the 
Ramachandran plot.   
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Dihedral angle restraints can be predicted on the basis of chemical shift values using the 
software program TALOS-N (Shen et al., 2013).  TALOS-N compares the chemical shift values 
of HA, Cα, Cβ, CO, N, and NH for a given residue to the chemical shift values from a protein 
database.   
 
Hydrogen bonds in protein secondary structure prevent efficient exchange of amide 
protons with the surrounding solvent.  Therefore, hydrogen bonded amide protons can be 
identified by measuring hydrogen-deuterium (H/D) exchange rates (Figure 2.26).  To measure 
H/D exchange rate, water in the sample is replaced with deuterium oxide (D2O), followed by 
recording successive 2D 15N-HSQC experiments.  NMR peaks of amide protons that rapidly 
exchange with the D2O solvent lose intensity at a faster rate because deuterium (2H) is not 
observable in proton (1H) NMR.  By plotting the peak volumes as a function of time for each 
residue and extracting the exchange rate from the exponential decay curve, hydrogen bonded 
amide protons can be accurately identified.  
 
 
Figure 2.25: Protein structure determination by NMR spectroscopy.  Chemical shift 
assignment for the backbone and side-chain amino acids provide restraints for structure 
calculation.   
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Figure 2.26: The process of hydrogen-deuterium exchange for analyzing residues involved 
in hydrogen bonding.  (A) The anti-parallel β-sheet is dissolved in protonated (1H) buffer and 
(B) diluted into buffer containing D2O (2H2O).  Labile protons rapidly exchange with the 
surrounding D2O.  (C) Amides involved in hydrogen bonding are protected from the deuterium 
solvent and will exchange more slowly with the surrounding solvent.                    
 
The most important type of restraints in NMR structure determination is distance 
restraints.  The nuclear Overhauser effect (NOE) is a phenomenon that transfers magnetization 
from one nucleus to another through space (Overhauser, 1953).  The NOE is first achieved by 
irradiating a population of nuclei until it reaches saturation.  As the saturated population of atoms 
relaxes back to its equilibrium, magnetization is transferred to nearby atoms.  For structure 
determination, in particular, the NOE is used to derive distance restraints between two hydrogen 
atoms in space (Wüthrich, 1989).  The NOEs are a source of geometric information and can 
measure a range of distances for protons that are close together in three-dimensional space, even 
if they are far apart in the primary sequence.  NOEs can be used to calculate distances because 
the NOE peak volume is proportional to 1/r6, where r is the distance between the two protons 
(Williamson, 2006).  Since the observed NOEs decrease rapidly as the distance increases, the 
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practical detection limit between two protons is 5-6 Å.  Although the NOE peak volumes 
translate into interproton distances, it is not a precise measurement, and commonly NOE-derived 
upper distance limits are used instead of precise distances.  Strong NOEs reflect protons close 
together and weak NOEs reflect protons farther apart in space.  Three-dimensional 15N- and 13C-
NOESY experiments are used to measure NOE distance restraints (Gardner and Kay, 1998).   
 
The preliminary NMR solution structure is subsequently refined against a set of structural 
restraints containing chemical shift assignments, dihedral angle restraints, and NOE distance 
restraints.  The goal of NMR structure calculations is to find a global energy minimum for an 
ensemble of structures.  Molecular dynamics in torsion angle space (TAD) with simulated 
annealing is the most widely used algorithm for calculating NMR structures and is implemented 
in popular programs such as CYANA and XPLOR-NIH (Güntert, 1998; Schwieters et al., 2006; 
Stein et al., 1997).  This algorithm starts with an ensemble of random polypeptide chain 
conformations and a simulated annealing protocol is applied to each starting conformation.  The 
simulated annealing procedure heats the system to a very high temperature and applies fixed 
values to covalent bond lengths and angles, while allowing rotation about the single bonds.  As 
the temperature decreases in the SA protocol, inconsistent NOEs may trap the protein 
conformation in a local energy minimum.  Kinetic energy is applied to the system to escape such 
energy wells in order to reach a global energy minimum.  A target function describing the energy 
of the system is applied during structure calculations (Güntert, 1998).  The target function 
contains experimental terms such as distance restraints measured from NOE experiments and 
theoretical terms such as van der Waals interactions.  It determines whether the quality of the 
overall structure satisfies the experimentally determined distance and dihedral angle restraints.  
The target function increases when the structure deviates from the experimental data and violates 
physical parameters such as van der Waals interactions.  Therefore, a minimized target function 
commonly generates protein structures at a global energy minimum. 
 
To validate that the calculated NMR structures are correct, distance and dihedral angle 
restraint violations are analyzed.  NOE violations are manually assessed in an iterative manner to 
determine whether the distance restraints should be adjusted (Spronk et al, 2004).  The quality of 
the dihedral angle restraints in secondary structures is compared to the Ramachandran plot
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(Spronk et al., 2004).  A lower backbone root-mean-square deviation (RMSD) indicates 
improvement in the precision of the NMR structure.  The Protein Structure Validation Software 
Suite (PSVS) (Bhattacharya et al., 2006) integrates several software programs such as 
PROCHECK (Laskowski et al., 1993) and MolProbity (Lovell et al., 2003) to assess the quality 
of an NMR structure.      
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2.6 Nanobodies as probes to analyze dynamics and conformation of MBD1-6 in ATP7B 
2.6.1 Structural features of nanobodies 
The N-terminal region of ATP7B is a large multi-domain protein that is highly dynamic.  
It consists of six MBDs that are connected by flexible protein linkers.  Solving the structure of 
MBD1-6 at atomic resolution using traditional methods such as NMR and X-ray crystallography 
is challenging.  Highly mobile proteins cannot be crystallized because of insufficient crystal 
contacts.  Crystallization chaperones can force MBD1-6 into a stable conformation (Rasmussen 
et al., 2011), however, these may not be physiologically relevant.  On the other hand, solving the 
structure of MBD1-6 by NMR using the traditional NOE method may not be very accurate.  
NOE assignment ambiguity and the lack of long-range inter-domain NOEs are two major 
problems for solving the NMR structure of MBD1-6.  However, NMR is a powerful method that 
can provide important dynamic information in various timescales.  Protein dynamics may help us 
gain insight into the conformation of MBD1-6 and identify possible transient interactions 
between the individual MBDs.  In our studies, we have used nanobodies to probe the backbone 
dynamics of MBD1-6.  A nanobody is a single-domain antibody fragment, which binds to the 
target protein with high affinity and specificity (Muyldermans, 2013).  It is characteristic of 
conventional antibodies but is much smaller in size.  Large proteins that bind to MBD1-6 lead to 
fast relaxation, producing broad NMR linewidths and diminished spectral quality. The binding of 
conventional antibodies (150 kDa) or Fab fragments (50 kDa) to isotopically labeled MBD1-6 
would completely deteriorate the quality of the 2D 1H-15N HSQC spectrum, providing no useful 
structural or dynamic information.  On the other hand, the small size of a nanobody is 
particularly advantageous in NMR studies because the binding of a nanobody can change the 
structure or dynamics of specific individual MBDs without adversely decreasing the overall 
quality of the NMR spectra (Huang et al., 2014; Dmitriev et al., 2016).     
 
The conventional immunoglobulin G (IgG) antibody consists of two heavy and two light 
chains that are each 50 kDa and 25 kDa, respectively (Muyldermans, 2013) (Figure 2.27A).  
These chains are connected together by disulfide bonds and non-covalent interactions, forming a 
150 kDa protein complex.  The antigen binding properties are defined by the complementarity-
determining regions (CDRs) of the variable heavy and light chains.  The large size of the 
antibody has prompted the development of smaller antibody derivatives.  The Fab fragment is 
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approximately 50 kDa and contains two variable domains and a truncated heavy chain (Figure 
2.27A).  A single-chain fragment (scFV) was later developed that contains two variable domains, 
which are connected by a peptide linker.  Removal of the variable light chain in the scFv exposes 
a large hydrophobic surface that causes aggregation and poor solubility (Davies and Riechmann, 
1994; Ward et al., 1989).  The search for a small antibody derivative with optimal biochemical 
properties led to heavy-chain antibodies.    
 
Figure 2.27: Structural organization of (A) conventional IgG antibodies and (B) heavy-
chain antibodies.  The smallest antibody derivative from conventional and heavy-chain 
antibodies is scFV and nanobody, respectively.        
 
Heavy-chain antibodies (HCAbs) are found only in the Camelidae family (camels, 
llamas, and alpacas) and sharks.  These HCAbs are structurally similar to IgG, except that they 
lack the light chains (Muyldermans, 2013) (Figure 2.27B).  Since the isolated variable domain of 
HCAbs (VHH) does not contact any other domain in the antibody molecule, its surface is 
hydrophilic, and it does not aggregate in solution.  The unique properties of the VHH have 
spawned a new type of antibody derivative called a nanobody.   
 
A nanobody is an isolated, recombinant-produced variable domain of the heavy-chain 
antibody.  The core structure of a nanobody is composed of β-sheets, with the CDRs forming the 
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antigen-binding site (Desmyter et al., 1996) (Figure 2.28).  A significant difference between the 
structure of camel VHH and the VH domains from human and mouse is the length of CDR3 
(Desmyter et al., 1996).  The average length of the CDR3 is longer for camel VHH than the 
human and mouse CDR3.  Therefore, the nanobody CDR3 protrudes much farther from the 
surface of the core structure, which allows nanobodies to recognize epitopes that are unattainable 
with conventional antibodies (Figure 2.28).  Nanobodies are advantageous over conventional 
antibodies because of their small size (12-15 kDa), ease of recombinant expression, high 
solubility, and binding specificity.  
 
 
Figure 2.28: The crystal structure of a nanobody (magenta) bound to lysozyme (green).  
The CDR1-3 loops are shown in blue, cyan, and yellow, respectively.   
 
2.6.2 Nanobody production and selection 
 A detailed protocol for producing and selecting nanobodies has been published (Pardon et 
al., 2014) (Figure 2.29), and is briefly described here using MBD1-6 as an example.  Nanobodies 
for our work were generated in the laboratory of Dr. Serge Muyldermans at Free University of 
Brussels.  We have selected nanobodies that specifically bind to MBD1-6.  First, MBD1-6 was 
purified using affinity and ion-exchange chromatography (Figure 2.29A).  MBD1-6 was used as 
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an antigen for immunization in alpaca (Figure 2.29B).  As the immune response matured, mRNA 
was extracted from isolated peripheral blood lymphocytes and used to generate the cDNA library 
of the VHH by reverse transcription (Figure 2.29B).  The VHH cDNA library was subsequently 
used for selecting nanobodies by phage display, using MBD1-6 as an immobilized antigen 
(Figure 2.29C).  Multiple rounds of panning were performed to enrich for target-specific 
nanobodies.  The selected nanobodies were expressed in Escherichia coli with a histidine tag for 
one-step purification by Ni-NTA affinity chromatography (Figure 2.29D).   
 
Figure 2.29: Production and selection of nanobodies.  (A) MBD1-6 is expressed and purified 
by affinity and anion-exchange chromatography. (B) Alpaca is immunized with MBD1-6 and 
blood lymphocytes are obtained.  The mRNA is isolated to generate the cDNA library of the 
VHH.  (C) Phage display selects for nanobodies against MBD1-6.  (D) Nanobodies are expressed 
in E. coli and purified by Ni-NTA chromatography.          
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3 Materials and Methods 
3.1 Generation of protein constructs in the pTYB12 expression vector 
Recombinant DNA corresponding to the open reading frame of metal-binding domain 1 
of ATP7B was cloned into the pTYB12 expression vector (New England Biolabs).  The pTYB12 
vector is designed to fuse the N-terminus of the target protein to a self-cleavable intein tag that 
attaches to the chitin-binding domain (Chong et al., 1997) (Figure 3.1).  The chitin-binding 
domain in the expressed fusion protein attaches to chitin beads, allowing a single-step 
purification process (Chong et al., 1997).  The addition of DTT induces the self-cleaving activity 
of the intein, which releases the target protein from the CBD-intein tag (Chong et al., 1997).  
 
Figure 3.1: Map of pTYB12-MBD expression vector.   The MBD target gene (yellow) is 
inserted in-between the NdeI and SalI restriction sites and fused with the intein tag (purple).  The 
intein tag is attached to the chitin-binding domain (turquoise).  The plasmid is ampicillin 
resistant (blue) and expression is controlled by the IPTG-inducible lac promoter (green).               
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Dr. Natasha Dolgova previously designed the vectors that were used for expressing some 
of the proteins used in this work, and as starting points for generating expression vectors for 
others. The pTYB12 fusion construct containing MBD1-6 (pND11) was used as a template for 
cloning pCY_MBD1, pCY_MBD4, pCY_MBD1-3, and pCY_MBD5-6 (Table 3.1).  The mutant 
SxxS MBD1-4 (pND8) was used as a template for cloning pCY_MutMBD1.  Mutant G875R-A-
domain (pND23) was used in site-directed mutagenesis as a template for cloning the wild-type 
G875 A-domain.  The original hTrx1 plasmid (pET-3a-hTrx1) was a gift from Dr. David Sanders 
(Department of Chemistry; University of Saskatchewan) and was used as a template to sub-clone 
hTrx1 into the pTYB12 expression vector (pCY_hTrx1).    
 
Table 3.1: Summary of the plasmids used for expression and purification.  
Plasmid Name Target Expression Product Description 
pND11 MBD1-6 Encodes MBD1-6 of ATP7B 
pND8 Mutant SxxS MBD1-4 Encodes MBD1-4 of ATP7B 
with serine substitutions 
(CxxC à SxxS) 
pND23 G875R-A-domain Encodes A-domain with R875 
point mutation 
pET-3a-hTrx1 hTrx1 Encodes human thioredoxin   
Derivative plasmids from pND and pET vectors 
pCY_MBD1 MBD1 Encodes MBD1 of ATP7B 
pCY_MutMBD1 MBD1 Encodes mutant SxxS-MBD1 
of ATP7B 
pCY_MBD4 MBD4 Encodes MBD4 of ATP7B 
pCY_hTrx1 hTrx1 Encodes human thioredoxin 
pCY_MBD1-3 MBD1-3 Encodes MBD1-3 of ATP7B 
pCY_MBD5-6 MBD5-6 Encodes MBD5-6 of ATP7B 
pCY-Gly875_Adom A-domain Encodes Gly875 variant of 
A-domain 
 
Single colonies were selected, used to inoculate 5 mL LB media containing 100 µg/mL 
ampicillin, and grown overnight at 37 °C with shaking at 220 r.p.m.  All the plasmids were 
isolated from DH5α E. coli cultures using a QIAprep Spin Miniprep Kit (Qiagen) and eluted 
with 30 µL sterile water.  Plasmids were stored at -20 °C.   
 
All restriction exonucleases were supplied by New England Biolabs.  DNA restriction 
reactions were set up in 20 µL volumes with 0.5 – 2.0 µg of plasmid DNA, 5 U of each 
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restriction enzyme, and 2 µL of the appropriate 10 x NEB reaction buffer.  All PCR fragments 
incorporated 5’-NdeI and 3’-SalI restriction sites into the recombinant PCR product with the 
following primers (Table 3.2).   Both the pTYB12 vector and the desired PCR fragment were 
digested with NdeI and SalI restriction enzymes with incubation at 37 °C for 30 minutes.  The 
digested vector and PCR fragment were gel purified using the QIAquick gel extraction kit 
(Qiagen).  
 
Ligation reactions were set up in 20 µL volumes.  Each reaction contained 50 ng vector 
DNA, 80 ng inset DNA, 2 µL of 10 x T4 DNA ligase buffer, and 400 U of T4 DNA ligase 
(NEB).  Ligation mixtures were incubated overnight at 16 °C.  The resulting constructs were 
verified by automated DNA sequencing and transformed into E. coli BL21(DE3) cells for protein 
expression.   
   
Competent E. coli BL21(DE3) competent cells were prepared using CaCl2 
transformation.  Fifty microliters of competent cells were incubated with 0.3 µg plasmid DNA 
for 30 minutes on ice.  The cells were then heat shocked for 45 seconds at 42 °C and incubated 
on ice for ten minutes.  The cells were then transferred into 200 µL of LB media and incubated at 
37 °C for one hour with shaking at 550 r.p.m.  The cells were then plated on LB agar containing 
100 µg/µL ampicillin and incubated overnight at 37 °C. 
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Table 3.2: List of primers used in cloning. 
  Primer 
Name 
Sequence Description 
CY-MBD1F 5’- GAGCATATGCAGGTGGCCACCAGCACAGTC - 3’ Forward primer 
for metal-binding 
domain 1 
CY-MBD1R 5’ - CCAGTCGACTTATTCTGCAATGCTGGCCTCGA - 3’ Reverse primer for 
metal-binding 
domain 1 
CY-MBD4F 5’ - GAGCATATGACATGCAGTACCACTCTGATTGCC - 3’ Forward primer 
for metal-binding 
domain 4 
CY-MBD4R 5’ - GTGGTCGACTTAAGAAACGACTGAAGCCTCAAATCCC - 3’ Reverse primer for 
metal-binding 
domain 4 
CY-hTrxF 5’ - GAGCATATGGTGAAGCAG ATCGAGAGCAAGACTGC  - 3’ Forward primer 
for human 
thioredoxin 
CY-hTrxR 5’ - CGCGTCGACTTAGACTAATTC ATTAATGGTGGC - 3’ Reverse primer for 
human thioredoxin 
pAM-R1n 5’ - CCAGTCGACTTATTCTGCAATGCTGGCCTCGA  - 3’ Reverse primer for 
metal-binding 
domain 3 
ND-4028F 5’ - (P)CACTGTAATTGCGGGGTCTATAAA TGC - 3’ Forward primer 
for A-domain 
(Gly875) 
ND-4027R 5’ - (P)CTTCCGGGTTTCTTAGTGACTGG - 3’ Reverse primer for 
A-domain 
(Gly875) 
CY-MBD56F 5’ - GAG CAT ATG GCA CCG CAG AAG TGC TTC TTA - 3’ Forward primer 
for metal-binding 
domain 5-6 
CY-MBD56R 5’- CCA GTC GAC TTA CTG GGC CAG GGA AGC ATG - 3’ Reverse primer for 
metal-binding 
domain 5-6 
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3.2 Purification of Atox1 and metal-binding domains of ATP7B 
 The E. coli BL21(DE3) strain with a desired pTYB12 expression vector was grown in a 
shaking incubator and the expressed protein was purified using the following procedure.  Six 
litres of E. coli BL21(DE3)/pTYB12 cell culture were grown at 37 °C in Luria broth to OD600 of 
0.6-0.8 and pelleted by centrifugation at 6,000 x g.  The bacteria was re-suspended in M63 
minimal medium supplemented with 0.5 mg/L FeSO4, 0.3% glucose, and 100 mg/L ampicillin 
(Elbing and Brent, 1998).  For experiments that require isotopically enriched 15N and 13C protein, 
M63 minimal media was supplemented with 15NH4Cl and 13C-D-glucose as the sole nitrogen and 
carbon sources, respectively (Cambridge Isotopes).  Expression of the proteins was induced by 
the addition of 500 µM isopropyl β-d -1-thiogalactopyranoside (IPTG) followed by incubation at 
16 °C for 16-20 hours.  Cells were harvested by centrifugation at 6,000 x g for 15 minutes at 4 
°C.   
 
 Cells were homogenized and disrupted using a cell disruptor (Constant Systems Limited) 
at 35 kpsi.  The cell extract was centrifuged at 27,000 x g for 45 minutes, the supernatant was 
collected and subjected to chitin-affinity chromatography.  The column was loaded with 30 mL 
of chitin beads and equilibrated with three bed volumes of wash buffer (50 mM Tris-HCl pH 8.2, 
500 mM NaCl).  The supernatant was applied to the column at a rate of 0.5-1 mL/min.  Then the 
column was washed with 30 bed volumes of wash buffer at an unrestricted gravity flow rate, 
followed by 3 bed volumes of cleavage buffer (50 mM Tris-HCl pH 8.2, 150 mM NaCl, 50 mM 
DTT).  The column was then incubated for 2-3 days at 4 °C.  The proteins were eluted with 3 
bed volumes of cleavage buffer in 10 mL fractions and dialyzed overnight against 50 mM Tris-
HCl pH 8.2 and 50 mM NaCl to remove excess DTT from the eluted protein.   
 
 Additional purification of MBD1-6 after chitin-affinity chromatography was performed 
by anion-exchange chromatography.  The protein sample was loaded on a 5 mL HiTrap Q 
column (GE Healthcare), equilibrated with 10 column volumes of Buffer A (50 mM Tris-HCl 
pH 8.2, 50 mM NaCl, and 5 mM DTT).  The column was washed with 10 column volumes of 
Buffer A and eluted using a linear concentration gradient of 50-500 mM NaCl in Buffer A.  
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Protein purity was determined using sodium dodecycl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE). 
3.3 Nanobody expression and purification by Ni2+-affinity chromatography 
 E. coli WK6 cells with the pHEN6c expression vector were grown at 37 °C in TB media 
to OD600 of 0.6-0.9 (Pardon et al., 2014).  The growth media was supplemented with 1 mM 
MgCl2, 0.1% (w/v) glucose, and 100 µg/mL ampicillin (Pardon et al., 2014).  Nanobody 
expression was induced with 1 mM IPTG followed by incubation at 28 °C for 16-20 hours.  The 
nanobodies are expressed with a secretion signal that targets the nanobodies to the periplasm for 
easy purification and disulfide bond formation.   
 
 Cells were centrifuged at 9,000 x g for 15 minutes at room temperature, re-suspended in 
15 mL of TES (0.2 M Tris pH 8.0, 0.5 mM EDTA, and 0.5 M sucrose), shaken for 1 hour on ice, 
diluted with 30 mL of TES/4, and incubated for an additional 1 hour on ice.  The periplasmic 
proteins were collected by centrifugation at 10,000 x g for 30 minutes at 4 °C and purified using 
Ni-NTA resin (Pardon et al., 2014).   
 
3.4 NMR experiments and data analysis 
3.4.1 NMR sample preparation 
 For all NMR experiments, samples contained 50 mM HEPES pH 7.4, 50 mM NaCl, 5 
mM TCEP, 1 mM DSS, and 10% (v/v) D2O, unless otherwise specified.  All HSQC experiments, 
except for structure determination, were recorded at 298 K on a 600 MHz Bruker NMR 
spectrometer at Saskatchewan Structural Sciences Centre (SSSC), University of Saskatchewan, 
with a T1 relaxation delay of 1.1 seconds.  The spectrometer was equipped with either a triple-
resonance Cryoprobe with z-axis pulse field gradients or a TXI microprobe.  TROSY (Pervushin 
et al., 1997) and transverse relaxation experiments (Zhu et al., 2000) for MBD1-6 were acquired 
at 310 K on a 900 MHz Varian NMR spectrometer at the National Magnetic Resonance Facility 
at Madison (NMRFAM), University of Wisconsin.  This spectrometer was equipped with a 
triple-resonance cold probe with z-axis gradients, unless otherwise specified.     
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All data were processed using NMRPipe (Delaglio et al., 1995).  The HSQC, TROSY, 
and NMR transverse relaxation experiments were analyzed using NMRView (Johnson, 2004). 
 
3.4.2 Monitoring protein-protein interactions and metal-binding and -transfer by 
chemical shift perturbation analysis 
Metal-binding to Atox1 or MBD2.   
 Purified protein was incubated with 10 mM EDTA for 30 minutes on ice.  MBD2 was 
then dialyzed twice against 50 mM HEPES pH 7.4, 50 mM NaCl, and 0.6 mM TCEP for a total 
of eight hours and twice again against degassed 50 mM HEPES pH 7.4, 50 mM NaCl.  The 
protein was dialyzed for a total of 16 hours.  A cisplatin stock concentration of 4.5 mM was 
freshly prepared in degassed NMR buffer and was added to either Atox1 or MBD2 at a molar 
ratio of 1:1.   
 
Atox1-MBD2 and MBD2-GSH, -hTrx1, and hGrx1 cisplatin transfer experiments.   
Unlabeled Atox1 was pre-treated with cisplatin, as described above, at a 1:1 molar ratio.  
Unlabeled Atox1-Pt was concentrated to 0.5 mM, added to 15N-labeled MBD2 at a molar ratio of 
1:1, and then a series of 2D 15N-HSQC spectra were recorded.  For the reverse transfer 
experiment, unlabeled apo-Atox1 was added at a 2:1 molar ratio to 15N MBD2-Pt.    
 
The return of MBD2-Pt back to the apo form was examined in the presence of GSH, 
hTrx1, or hGrx1.  MBD2 was reacted with cisplatin, added to unlabeled hTrx1 or hGrx1 at a 1:1 
molar ratio, and a series of 2D 15N-HSQC spectra were recorded.  For the MBD2-GSH cisplatin 
transfer experiments, residual TCEP was removed from MBD2-Pt by gel filtration on a 
Superdex-200 column in a buffer containing 50 mM HEPES pH 7.4 and 50 mM NaCl.  GSH was 
then added to the protein to a final concentration of 5 mM.   
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Concentration of the MBD2-Pt complex was calculated according to the following 
equation:  
[MBD2-Pt] = [MBD2total]*VPt/(Vapo + VPt),       (3.1) 
 
where [MBD2total] is the total MBD2 concentration in the NMR sample, and VPt and Vapo are 
peak volumes of the backbone amide signal in the platinum-bound and apo form, respectively, in 
the 1H, 15N-HSQC spectrum recorded at a given time after the addition of cisplatin, carboplatin, 
GSH, hGrx1, or hTrx1.  G27 was the reporter group for measuring the peak volume of MBD2-Pt 
in the presence of cisplatin, carboplatin, and GSH, whereas G15 was used for measuring the peak 
volume of MBD2-Pt in the presence of hGrx1 and hTrx1.  
 
Interaction between MBD1, MBD2, and MBD3 and molecular modeling.  
 Domain-domain interactions using chemical shift perturbation analysis were performed 
using three pairs of isolated MBDs: MBD1-MBD2, MBD1-MBD3, and MBD2-MBD3.  To 
determine contact surfaces between the individual MBDs, both the unlabeled and 15N-labeled 
forms of MBD1, MBD2, and MBD3 were purified.  For each 15N-labeled protein, the unlabeled 
partner protein was added at a 1:1 molar ratio to a final protein concentration of 150 µM.  A 2D 
15N-HSQC spectrum was recorded before and after the addition of the unlabeled protein to 
measure chemical shift changes.  The chemical shift changes of the isotopically labeled protein 
were submitted as docking restraints in the program, HADDOCK (de Vries et al., 2010).  1000 
initial structures were generated by rigid-body docking using ambiguous distance restraints and 
the 200 lowest energy structures were subsequently refined with simulated annealing (de Vries et 
al., 2010).  A final cycle with explicit water refinement was used and ten clusters were generated 
based on the backbone RMSD of all the atoms in the complex.  These final clusters were ranked 
according to the sum of interaction energies as reported by the HADDOCK program (de Vries et 
al., 2010) and the cluster with the most negative HADDOCK score was selected to represent the 
MBD1-MBD3 interaction surface.            
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3.4.3 Chemical shift assignment and structure determination of MBD1 
 Backbone chemical shift assignments for MBD1 were made from HNCO, HNCA, 
HNCACB, HN(CA)CO, and HN(CO)CACB (Gardner and Kay, 1998).  Side-chain assignment 
experiments were done using H(CCO)NH, CC(O)NH, AND 1H, 15N-TOCSY (Gardner and Kay, 
1998).  The parameters for the backbone- and side-chain experiments for the structure 
calculation of MBD1 are listed in Table 3.3.  All of the chemical shift assignment experiments 
were performed at 298 K on a Bruker NMR spectrometer operating at 750 MHz 1H Larmor 
frequency (NMRFAM) and the backbone chemical shifts were assigned using CARA (Keller, 
2005).  The assignments have been deposited at BioMagResBank (accession no. 25827).  Peak 
tables and distance restraints were generated using the program, PONDEROSA (Lee et al., 
2011), from 3D 1H, 15N-NOESY and 3D 1H, 13C-NOESY experiments.  NMRFAM-SPARKY 
(Lee et al., 2015) was used in conjunction with PYMOL (DeLano, 2005) in PONDEROSA-C/S 
to manually validate NOE distance restraints and assignments (Lee et al., 2014).  The structure 
was calculated using the PONDEROSA-X option in PONDEROSA-C/S, which is an XPLOR-
NIH based structure calculation software package (Schwieters, et al., 2006).  The structural 
ensemble of MBD1 consists of the 20 best structures chosen from a total of 100 structures, based 
on the lowest energy and fewest violations.  The atomic coordinates have been deposited at the 
Protein Data Bank (ID code 2N7Y).       
 
 Hydrogen bond distance restraints for MBD1 were derived from H/D exchange 
measurements.  MBD1 was transferred from the standard NMR buffer to the same buffer (50 
mM HEPES pH 7.4, 50 mM NaCl, and 5 mM TCEP) prepared in 100% D2O using a NAP-5 
desalting columns (GE Healthcare).  A series of 1H-15N HSQC experiments were recorded 
immediately after buffer exchange over a period of 12 hours and the peak volume change was 
measured as a function of time.  
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Table 3.3: Acquisition parameters for the NMR structure determination experiments for 
MBD1.   
Experiments Dimension of acquired 
data 
Spectral width (ppm) Number of 
scans 
 t1 t2 t3 F1 F2 F3  
HNCO 64 
(13C) 
96 
(15N) 
2048 
(1H) 
15 40 16 8 
HNCA 112 
(13C) 
96 
(15N) 
2048 
(1H) 
15 40 16 8 
HNCACB 160 
(13C) 
96 
(15N) 
2048 
(1H) 
40 40 16 8 
HN(CA)CO 64 
(13C) 
96 
(15N) 
2048 
(1H) 
15 40 16 16 
HN(CO)CACB 160 
(13C) 
96 
(15N) 
2048 
(1H) 
55 40 16 8 
H(CCO)NH 128 
(13C) 
48 
(15N) 
2048 
(1H) 
16 40 16 16 
CC(O)NH 128 
(13C) 
64 
(15N) 
2048 
(1H) 
75 40 16 16 
1H-15N TOCSY 
HSQC 
164 
(13C) 
40 
(15N) 
2048 
(1H) 
12 40 16 16 
15N-NOESY 256 
(13C) 
96 
(15N) 
2048 
(1H) 
11 40 16 8 
13C-NOESY 256 
(13C) 
80 
(15N) 
2048 
(1H) 
14 75 16 8 
 
3.4.4 Transverse relaxation studies of nanobody-binding and Atox1-Cu transfer to 
MBD1-6 
 To prepare samples for NMR relaxation analysis, nanobodies were added in equimolar 
ratios to MBD1-6.  Unlabeled Atox1 was pretreated with Cu(I) at a 1:1 molar ratio and 
subsequently added to MBD1-6 at a 6:1 molar ratio.  Longitudinal (R1) relaxation, transverse 
relaxation (R2), and heteronuclear 15N{1H}-NOEs were only measured for nanobody-free and 
R50-bound MBD1-6.  To determine the R1 relaxation rates of the individual domains, several 
spectra were collected with different relaxation delays ranging from 0 to 1200 ms. For the R2 
relaxation rates of the individual domains in each experiment, several 1H-15N HSQC spectra 
were collected with different relaxation delays ranging from 0 to 140 ms (Zhu et al., 2000) 
(Table 3.4). The relaxation rates were extracted using NMRView (Johnson, 2004) by 
exponentially fitting the peak intensities to a series of 1H, 15N-TROSY spectra.  The 
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heteronuclear 15N{1H}-NOE values were determined from the ratio of peak intensities measured 
with and without proton saturation.      
 
Dr. Sergiy Nokhrin calculated the correlation times (τc) of the individual metal-binding 
domains in apo- and R50-bound MBD1-6 from the relaxation rates and 1H-15N heteronuclear 
NOE data using the TENSOR V2 program (Dosset et al., 2000).   
 
Table 3.4: Acquisition parameters for the MBD1-6 transverse relaxation experiments.   
R2 
relaxation 
of 15N 
MBD1-6 
Type of 
relaxation 
experiment 
Dimension 
of acquired 
data 
Spectral 
width 
(ppm) 
Number of 
Experiments 
Relaxation 
delays (ms) 
  t1 t2 F1 F2   
Apo 
MBD1-6 
R1 256 
(15N) 
2048 
(1H) 
33 16 7 0, 100, 180, 
340, 500, 
800, 1200 
 R2 256 
(15N) 
2048 
(1H) 
33 16 7 10, 20, 40, 
60, 80, 110, 
140 
R50 R1 256 
(15N) 
2048 
(1H) 
33 16 7 0, 100, 180, 
340, 500, 
800, 1200 
 R2 256 
(15N) 
2048 
(1H) 
33 16 7 10, 20, 40, 
60, 80, 110, 
140 
1R1 R2 256 
(15N) 
2048 
(1H) 
33 16 7 10, 20, 30, 
40, 50, 70, 
100 
Apo 
Atox1 
R2 256 
(15N) 
2048 
(1H) 
33 16 8 10, 20, 30, 
40, 60, 80, 
100, 120 
Atox1-Cu R2 256 
(15N) 
2048 
(1H) 
33 16 8 10, 20, 30, 
40, 60, 80, 
100, 120 
 
3.5 Domain orientation studies of MBD1-3 using Small Angle X-ray Scattering 
 MBD1-3 was expressed and purified, as described above.  Size-exclusion 
chromatography on a Superdex 75 column was performed to remove protein aggregates.  MBD1-
3 was dialyzed in SAXS buffer (50 mM HEPES pH 7.4, 50 mM NaCl, and 5 mM TCEP) for 36-
48 hours.  MBD1-3 data was collected on a Bruker NANOSTAR spectrometer with a Bruker 
	 		 	
	 54		
Turbo rotating Cu-anode x-ray source (NMRFAM).  The dialysis buffer scattering signal was 
subtracted from the MBD1-3 scattering signal. The optimal scattering signal was recorded with 
2.0 mg/mL of MBD1-3.  Scattering data was analyzed using PRIMUS (Konarev et al., 2003) and 
other programs from the ATSAS software package (Petoukhov et al., 2012).    DAMMIF (Franke 
and Svergun, 2009) was used to generate 10 independent ab initio dummy atom models from the 
experimental SAXS data.  
3.6 Other analytical methods 
3.6.1 SDS-PAGE 
 SDS-PAGE was performed as described by Schägger and von Jagow (Schägger et al., 
1988).  The stacking gel layer contained 3% acrylamide and the separating gel contained 10% 
acrylamide.   
 
3.6.2 Protein determination by the BCA method 
 Protein concentration determination was carried out as previously described (Smith et al., 
1985).  BSA standard curves ranging from 0 µg – 50 µg per sample were conducted with each 
assay.  
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4 Results 
4.1 Preliminary NMR studies and the strategy for the structural analysis of MBD1-6.     
 Currently, there is no high-resolution structure of the entire N-terminal region, 
encompassing all of the copper-binding domains.  The structures of several individual MBDs, 
including MBDs 2 through 6, have been solved using NMR (Achila et al., 2006; Banci et al., 
2008; Dolgova et al., 2013) and the copper binding affinities for each domain have been 
determined (Ka = 2.2 x 10-10 to 6.0 x 10-10 M-1) (Yatsunyk and Rosenzweig, 2007).  Each domain 
consists of a ferredoxin-like fold (βαββαβ), where the characteristic copper-binding CxxC motif 
is in a loop region between β1-strand and α1-helix.  Copper binding to each domain does not 
induce significant conformational changes of the individual domain, only affecting the region in 
and adjacent to the copper-binding motif (Achila et al., 2006; Banci et al., 2008).  However, this 
effect can be relayed along the protein backbone and cause significant structural rearrangements 
to other parts of MBD1-6 (DiDonato et al., 2000).  Therefore, the overall spatial organization of 
MBD1-6 and the interactions between specific MBDs are critical for understanding ATP7B 
transport and regulation.   
 
The 1H, 15N HSQC spectrum of MBD1-6 is well resolved for a protein with a molecular 
weight of 66 kDa (Banci et al., 2009a; Fatemi et al., 2010).  The observed narrow linewidths 
suggest that the individual MBDs are highly dynamic.  This observation is consistent with the 
high mobility of the MBD in the bacterial Cu+-ATPase structure (Gourdon et al., 2011).  By 
extension, this suggests that the six MBDs in ATP7B, which are connected by flexible linkers, 
are also highly dynamic and not amenable to X-ray crystallography.     
 
 Our goal was to investigate the conformation of full-length MBD1-6 and identify 
transient interactions between groups of MBDs using multi-dimensional and transverse 
relaxation NMR.  Recombinant MBD1-6 was successfully expressed in the pTYB12 vector.  We 
have optimized the purification of 15N MBD1-6 using chitin-affinity chromatography followed 
by anion-exchange chromatography (Figure 4.1B).  This purification process produced a yield of 
0.4 mg/L cell culture with a protein purity of 95%.  MBD1-6 produced a well-resolved 1H, 15N 
TROSY spectrum and the sample was stable for several days at a protein concentration of 160 
µM at pH 7.4.  
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Figure 4.1: Purification of the metal-binding domains.  Eluted fractions of purified (A) 
MBD1 purified by chitin-affinity chromatography and (B) MBD1-6 after chitin-affinity and 
anion-exchange chromatography.  Protein fractions were analyzed by 10% SDS-PAGE and 
stained with Coomassie R250.  The molecular weight of MBD2 is 8 kDa and MBD1-6 is 66 
kDa.   
 
The narrow linewidths in the spectrum imply that the individual MBDs in the full-length 
N-terminal region are highly dynamic.  This suggests that MBD1-6 represents a “beads-on-a-
string” model, with each MBD rotating independently from the others.  Having obtained a high 
quality 1H, 15N-TROSY spectrum of MBD1-6 at 900 MHz, we assigned approximately 68% of 
the peaks using a previously established chemical shift assignment of ATP7B MBD1-6 (Banci et 
al., 2009a) (Figure 4.2).  However, the first step in investigating the dynamics of MBD1-6 was to 
solve the structure of MBD1, the only domain whose structure was still missing. 
 
Figure 4.2: 1H, 15N-TROSY spectrum of MBD1-6 recorded at 900 MHz with some 
sequential assignments shown.  
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4.2 NMR structure of the metal-binding 1 of ATP7B 
We solved a high-resolution structure of MBD1 using multi-dimensional NMR.  MBD1 
was purified by chitin-intein affinity chromatography to a 95% purity, producing a yield of ~1 
mg/L of cell culture (Figure 4.1A).  This purification protocol produced a folded protein based 
on the well-dispersed amide signals in the 1H, 15N-HSQC spectrum (Figure 4.3).  Using standard 
triple resonance backbone and side-chain experiments with 13C, 15N-labeled MBD1, we assigned 
72 out of 76 non-proline backbone residues (Figure 4.3).  The unassigned backbone residues 
were A1, Q5, T17, and L58 (Figure 4.4B).  Based on the structure of MBD2 of ATP7B (Dolgova 
et al., 2013), these residues were predicted to be located in flexible regions of the protein.  The 
lack of backbone amide signal for these residues may be caused by increased chemical exchange 
with the surrounding solvent.   
 
Figure 4.3: 1H, 15N-HSQC spectrum of ATP7B MBD1 with the backbone amide 
assignments shown.   
 
The secondary structural elements of MBD1 were predicted by Talos-N (Shen and Bax, 
2013) (Figure 4.4C).  Since chemical shifts are strongly correlated with local secondary 
structure, Talos-N uses the 1Hα, 15N, 13Cα, 13Cβ, and 13C’ chemical shifts from a protein 
database to predict the values for the backbone φ and ψ dihedral angles (Shen and Bax, 2013).  
MBD1 forms the characteristic ferredoxin fold (βαββαβ), which is consistent with the other 
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MBDs of ATP7B (Achila et al., 2006; Banci et al., 2008; Dolgova et al., 2013; Fatemi et al., 
2010) and ATP7A (Banci et al., 2004; DeSilva et al., 2005).  
 
When at least 85% of the backbone and side-chain residues were assigned, the solution 
structure was calculated by incorporating assigned NOESY peak volumes of atoms from 3D 15N- 
and 13C-NOESY experiments.  After several iterations of preliminary structure calculations, 48 
hydrogen bond restraints were included in the structure calculation from hydrogen-deuterium 
(H/D) exchange experiments to help stabilize the secondary structures.  The final solution 
structure of MBD1 was determined using 628 distance restraints obtained from automated NOE 
peak picking from 3D 15N- and 13C-NOESY experiments (Lee et al., 2011) and 119 dihedral 
angle restraints from Talos-N (Shen and Bax, 2013) (Figure 4.4A).  The MBD1 structure was 
calculated using Xplor-NIH from the NMR structure determination package, PONDEROSA C/S 
(Lee et al., 2014).  Xplor-NIH calculates protein structures by simulated annealing using torsion 
angle/rigid body dynamics.  After energy minimization with explicit water refinement, the 
average backbone RMSD between the 20 calculated structures was 0.15 Å.  Table 4.1 reports on 
the structural statistics and restraint violations of the final structural ensemble of MBD1 
validated by the Protein Structure Validation Software Suite (Bhattacharya et al., 2006).   
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Figure 4.4: Structure determination of MBD1.  (A) The structural ensemble of MBD1 with 
the α-helices in red-yellow and the β-sheets in blue.   (B) Ribbon diagram showing the CxxC 
motif (blue) and the location of the unassigned backbone residues (orange).  (C) Amino acid 
sequence of MBD1 with secondary structural elements shown.   
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Table 4.1: Statistics for the structure calculation of MBD1.  
 
 
We analyzed the Cu(I) binding residues of MBD1, which aided in the assignment of 
unknown backbone amides for MBD1.  Copper(I) chloride was titrated at various ratios into 15N-
labeled MBD1, and Cu(I) binding was monitored by chemical shift perturbation analysis.  
Consistent with the other MBDs, Cu(I) binds to MBD1 in the slow exchange regime, which 
indicates a tight binding affinity (Figure 4.5; top left).  To assess the structural effects of Cu(I) 
binding on MBD1, the combined 1H-15N chemical shift changes were quantified as a function of 
amino acid residue (Figure 4.5; middle left) and mapped onto the solved NMR structure (Figure 
4.5; bottom).  Consistent with the other MBDs, Cu(I) binding to MBD1 caused significant 
chemical shift changes in the CxxC motif and a few adjacent residues (Figure 4.5; bottom left).  
However, comparing the effects of copper binding to MBD2, copper binding to MBD1 also 
affected residues in the N-terminal region of α2.    
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Figure 4.5: Copper binding to MBD1 (left) and MBD2 (right) analyzed by 1H, 15N-HSQC 
spectroscopy.  (Top)  Overlay of apo- (black) and copper-bound (red) MBD1 and MBD2 with 
assignments of peaks showing significant copper-dependent chemical shift changes;  (Middle) 
Combined chemical shift changes caused by copper binding as a function of amino acid residue 
number.  (Bottom)  Regions of the MBD1 and MBD2 structure affected by copper binding. 
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4.3 Transient interactions of metal-binding domains revealed by nanobody binding.  
4.3.1 Identification of nanobody-binding sites in MBD1-6 
In order to understand the molecular mechanism of copper acquisition and regulation of 
ATP7B, we analyzed MBD1-6, the protein construct with all six MBDs.  Although NMR is often 
limited to smaller proteins compared to X-ray crystallography, it can provide important 
information on protein dynamics.  We characterized the dynamics of MBD1-6 by measuring the 
NMR relaxation parameters: spin-lattice relaxation (R1), transverse relaxation (R2), and 
heteronuclear NOE.  Using these NMR relaxation parameters, we calculated a correlation time 
(τc) for each MBD.  The correlation time is the average time it takes a molecule to rotate one 
radian (Reddy and Rainey, 2010).  For a compact globular protein, the correlation time is 
approximately proportional to its molecular weight (Reddy and Rainey, 2010).   
 
Previous biochemical studies using AxxA mutant variants of MBD2 or MBD3 demonstrated 
a total loss of copper binding in MBD1-6 (LeShane et al., 2010).  This result suggests that inter-
domain communication of the MBDs regulates the conformation and function of the entire N-
terminal region.  However, the NMR data offer a different conclusion from the biochemical 
studies.  The narrow peaks in the 1H, 15N TROSY spectrum of MBD1-6 indicate independent 
tumbling of the individual MBDs.  This suggests that MBD1-6 represents a “beads-on-a-string” 
model.  The rotational correlation times (τc) of the individual MBDs in the context of MBD1-6 
range from 5.52 ns to 7.83 ns (Table 4.3).  These values are more consistent with independent 
tumbling of isolated MBDs than a compact globular protein of 66 kDa, which would have a τc of 
~30 to 40 ns (Dayie et al., 1996).  We hypothesized that these domain-domain interactions 
observed in biochemical studies are transient.   
 
To identify possible domain-domain interactions, nanobodies were used to probe the 
backbone dynamics of MBD1-6 (Figure 4.6).  Nanobodies are 12-15 kDa recombinant single-
domain antibodies derived from the heavy-chain antibodies found in the Camelidae species (see 
section 2.6.1) (Muyldermans, 2013).  We have identified the binding sites for a panel of 
nanobodies against MBD1-6.  Using established NMR chemical shift assignments and chemical 
shift perturbation analysis, we characterized a total of 16 nanobodies that bind to MBD1-6 and 
determined that 3 nanobodies bind to MBD3, 13 nanobodies to MBD4 (Table 4.2), and none to 
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any other MBDs. We subsequently estimated the nanobody-binding affinities using NMR by 
analyzing the chemical exchange of the MBD residues affected by nanobody binding. Residues 
that are involved in nanobody binding can either undergo slow, intermediate, or fast exchange 
(see section 2.5.4).  Slow exchange is correlated with tight binding (KD < 1 µM) and is 
manifested by two distinct peak signals, corresponding to the free- and ligand-bound forms in the 
NMR spectrum.  In contrast, fast exchange is associated with weak binding (KD > 100 µM).  In 
the fast exchange regime, only one peak is observed.  Intermediate exchange is correlated with a 
moderate binding affinity (KD ~ 1-100 µM) and is observed by the broadening of peaks and even 
complete signal disappearance.  The nanobodies against MBD3 have a moderate to tight binding 
affinity, whereas nanobodies against MBD4 show a wide range of binding affinities (Table 4.2).    
 
Since complete MBD1-6 was used for immunization, the original cDNA library should 
contain nanobodies against all the MBDs of MBD1-6.  However, in the initial selection process, 
only nanobodies against MBD3 or MBD4 were isolated.  This may suggest that MBD3 and 
MBD4 are more exposed in full-length MBD1-6, leading to higher immunogenicity of these 
domains.   
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Figure 4.6: A model for the panel of nanobodies that were generated against MBD1-6.   
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Table 4.2: Summary of nanobody properties.  Nanobodies are divided into groups based on 
the target domain (MBD3 or MBD4) and binding affinity (tight, KD < 1 µM; moderate, KD ~ 1-
100 µM; weak, KD > 100 µM).    
 
 
Chemical shift perturbation analysis was also used to determine the specific nanobody-
binding site on the target MBD.  In the ELISA assay, the R21 nanobody bound to apo- and 
copper-bound ATP7B equally well, whereas the R50 nanobody showed a preference for copper-
bound ATP7B (data not shown).  In our analysis, we determined the specific binding epitopes of 
two nanobodies, R50, against MBD3 (Fig 4.7A) and R21, against MBD4 (Fig 4.7B).  The R50 
nanobody caused chemical shift changes mostly in the C-terminal region of α1 and the adjacent 
loop connecting α1 to β2 of MBD3 (Fig 4.7C).  In contrast, R21 nanobody binding to MBD4 
caused small chemical shift changes in the loop connecting β2 and β3 (Fig 4.7D).  Since R21 
nanobody binding to MBD4 was weak, we did not use it for subsequent relaxation studies.    
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Figure 4.7: Binding sites of the R50 and R21 nanobodies.  Chemical shift changes caused by 
(A) R50 and (B) R21 nanobody binding to MBD1-6 as a function of amino acid residue number.  
Regions of (C) MBD3 and (D) MBD4 that are affected by R50 and R21 nanobody binding, 
respectively.     
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4.3.2 Nanobody binding to MBD3 and MBD4 caused distinct effects on MBD1-6 
dynamics.   
We used nanobodies to probe the backbone dynamics of MBD1-6 to gain insight into the 
dynamics and inter-domain interactions of the MBDs.  For these studies, we selected two high-
affinity nanobodies, one that binds to MBD3 (R50), and the other to MBD4 (1R1).  Transverse 
relaxation is influenced by the molecular motions of surrounding spins and hence, is an accurate 
indicator of protein dynamics (Reddy and Rainey, 2010). We measured the difference in 
transverse relaxation rates (R2) of each individual domain in the context of full-length MBD1-6 
in the free- and nanobody-bound forms (Figure 4.8A).  In the presence of R50, the transverse 
relaxation rate of MBD3 increased, which is consistent with the increased molecular mass of the 
MBD3-nanobody complex (Figure 4.8B).  Unexpectedly, the relaxation rates of MBD1-2 
significantly decreased, whereas MBD4-6 remained relatively unaffected.  This indicates that 
transient interactions exist between MBD1, MBD2, and MBD3 and that these interactions were 
disrupted by R50 binding to MBD3, increasing the mobility of MBD1 and MBD2.  In contrast, 
1R1 significantly decreased the mobility of MBD4 and a lesser extent to the other MBDs (Figure 
4.8A).  This suggests that the slower tumbling of nanobody-bound to MBD4 partially propagated 
to the other domains of ATP7B (Figure 4.8B).   
 
The measurements of transverse relaxation suggest a differential effect of nanobodies on 
MBD mobility.  This was confirmed by calculating the τc for each individual MBD from the R2 
and R1 measurements (Table 4.3).  If MBD1-6 (66 kDa) was a compact globular protein, the 
expected τc MBD would be ~30-40 ns.  In contrast, if MBD1-6 represented a “beads-on-a-string” 
model, the expected τc for each individual MBD in the context of MBD1-6 would be similar to 
the τc measured for isolated MBDs, around ~4.5-6 ns (Anastassopoulou et al., 2004; Banci et al., 
2008; Fatemi et al., 2010; Huang et al., 2014).  The correlation times that we calculated for the 
individual MBDs in the context of full-length MBD1-6 ranged from 5.5 ns to 7.8 ns.  This 
indicates that the dynamics of the individual MBDs are largely independent.  However, the τc for 
MBD1 (7.83 ns), MBD2 (7.5 ns), and MBD5 (7.19) were slightly higher than those of isolated 
MBDs.  This may indicate that inter-domain interactions could be involved.  We also observed 
differences in tumbling times for the individual domains that were affected by R50 nanobody 
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binding.  When the R50 nanobody binds, the τc of MBD3 increased from 6.3 ns to 8.26 ns, which 
is consistent with increased molecular mass.  In contrast, the τc of MBD1 and MBD2 decreased 
from ~7.5 ns to 5.5 ns, which is consistent with increased motional freedom.  The calculated τc 
values agree with the transverse relaxation behavior described for the individual MBDs.      
 
Table 4.3: The correlation times of the individual metal-binding domain in the context of 
MBD1-6. 
 
 
Figure 4.8: Transverse relaxation rate of MBD1-6 bound to R50 or 1R1 nanobody.  The 
difference between the transverse relaxation rates R2 in the absence and presence of the R50 and 
1R1 nanobody plotted as a function of residue sequence number.  (B) Model of MBD1-6 
indicating the change in dynamics of the individual MBDs when R50 or 1R1 nanobody binds.   
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4.4 MBD1-3 adopts a unique S-shaped conformation 
Transverse relaxation studies of MBD1-6 with the R50 nanobody have demonstrated 
correlated dynamics of MBD1-3 that were distinct from the rest of the N-terminal region. We 
propose that the N-terminal region of ATP7B is composed of two sets of correlated domains, 
MBD1-3 and MBD5-6.  The solution structure of MBD5-6 is connected by a short-linker of four 
amino acids and NMR relaxation measurements indicate that MBD5-6 tumbles as a rigid 
dumbbell (Achila et al., 2006).  Since the copper-binding sites of MBD5 and MBD6 face away 
from each other, copper transfer between these domains is not likely.  An alternative mechanism 
would involve copper transfer from MBD1-3 to MBD5-6.  However, there is currently no 
structural or dynamic information for MBD1-3.  We hypothesized that transient interactions exist 
within MBD1-3.  If MBD1-3 (29 kDa) is a compact globular protein, the expected τc would be 
~15-17 ns.  In contrast, if the dynamics of MBD1-3 are completely independent, the expected τc 
would be ~4.5-6 ns, similar to those of isolated MBDs.  The calculated τc of the individual 
MBDs in MBD1-3 range from 6.37 ns to 7.83 ns (Table 4.3).  These values are slightly higher 
than those of isolated MBDs, which may suggest that the individual MBDs in MBD1-3 are 
highly mobile with some inter-domain interactions involved.  This increased mobility is 
supported by the narrow resonances in the 1H-15N HSQC spectrum of MBD1-3 (Figure 4.9).  
Therefore, we used a combination of SAXS and molecular modeling as preliminary experiments 
to analyze the conformation of MBD1-3.    
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Figure 4.9: 1H-15N overlay of MBD1-6 TROSY spectrum (black) recorded at 900 MHz and 
MBD1-3 HSQC spectrum (red) recorded at 600 MHz.   
 
 
Figure 4.10: The envelope of MBD1-3 determined by SAXS. (A) The buffer-subtracted 1D 
scattering curve of apoMBD1-3.  (B) The surface representation of MBD1-3 generated from ab 
initio modeling.  The structures of individual MBD1-3 were manually fitted into the surface 
representation, based on the experimental nanobody relaxation data and chemical shift 
perturbation analysis. 
 
SAXS is a low-resolution technique that was used to determine the overall shape of 
MBD1-3 in solution state.  The optimal scattering data was collected on a monodisperse sample 
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for apoMBD1-3 at 2.0 mg/mL.  The Guinier region was extracted from the 1D scattering curve 
and measured a radius of gyration (Rg) of 31.4 Å (Figure 4.10A).  From the 1D scattering curve, 
ab initio modeling showed that the overall fold of MBD1-3 is S-shaped (Figure 4.10B).  We 
manually fitted the positions of the MBDs based on the interpretation of correlation time changes 
observed in the nanobody experiments.  In the absence of R50 nanobody, the correlation times 
for MBD1 and MBD2 were ~7.7 ns.  When the R50 nanobody was bound to MBD3, the τc for 
both MBD1 and MBD2 decreased to ~5.6 ns, which is close to the τc of 4.5 ns observed for an 
isolated MBD.  This suggests that MBD1 and MBD2 do not interact with each other, but each of 
them interacts with MBD3.  To map contacts between the domains, we analyzed pairwise 
domain interactions by NMR and molecular modeling.   
 
Domain-domain interactions between metal-binding domains 1, 2, and 3 were determined 
using chemical shift perturbation analysis.  Chemical shifts are highly sensitive indicators of the 
changes in the chemical environment of a given spin.  To analyze the contact surface of MBD1-
3, we purified MBD1, MBD2, and MBD3 in both the unlabeled and 15N-labeled form.  We 
measured chemical shift changes in the 1H, 15N-HSQC spectrum of each MBD caused by the 
addition of each of the other two MBDs in the unlabeled form.  For example, we recorded the 
1H, 15N-HSQC spectra of MBD1 with no addition, and either unlabeled MBD2 or unlabeled 
MBD3.  We observed reciprocal interaction between MBD1 and MBD3.  The interaction 
between MBD1 and MBD3 mainly affected the residues in the CxxC copper-binding motif.  
Additionally, the copper-binding residues of 15N MBD2 were affected by the interaction of 
unlabeled MBD1 or MBD3.  Surprisingly, unlabeled MBD2 caused no changes in the spectrum 
of 15N-MBD1 or 15N-MBD3 (Table 4.4).  We were not able to use MBD2 in our molecular 
modeling because of the lack of consistent chemical shift perturbation data in our preliminary 
experiments.       
 
We used NMR chemical shift perturbation data to dock MBD1 and MBD3 using 
HADDOCK, a molecular modeling program that uses experimental data at the protein-protein 
interface to drive the docking of two proteins (de Vries et al., 2010).    Based on the docked 
model, the cysteines in the copper-binding motif appear to be in close proximity to each other 
(Figure 4.11).  This close proximity of the copper-binding sites has been suggested to determine 
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the oxidation state and conformation of the entire N-terminal region (LeShane et al., 2010).  This 
molecular model of MBD1-MBD3 also agrees with our S-shaped envelope that we measured 
with SAXS.  HADDOCK was not used for the domain pair MBD1-MBD2 because our NMR 
relaxation data suggest that interactions between these two domains are negligible.  In addition, 
the domain pair MBD2-MBD3 was not modeled because of insufficient restraints.           
 
Table 4.4: Domain-domain interactions were analyzed by 1H, 15N NMR spectroscopy.  
Affected residues in the 15N partner protein were recorded and used an input in the program, 
HADDOCK.   
 
 
 
 
Figure 4.11: The molecular docking of MBD1 (green) and MBD3 (orange).  The copper-
binding motifs are highlighted (blue).   
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4.5 Interaction with Atox1-Cu changes domain dynamics and disrupts MBD1-MBD2 
association. 
4.5.1 Atox1 does not require copper to interact with the metal-binding domains.   
 Atox1 is a chaperone that delivers copper to the MBDs of ATP7B in the cell and has 
been shown to regulate copper transport activity of ATP7B.  Atox1 was shown to bind and 
transfer Cu(I) specifically to MBD2 in the context of full-length MBD1-6 (Walker, 2004).  To 
determine whether Cu(I) was required for Atox1 to interact with the MBDs, we investigated the 
interaction of apo-Atox1 with MBD1-6.  Unlabeled Atox1 was added at a 6:1 molar ratio to 15N-
MBD1-6.  Based on the lack of distinct chemical shift changes in the 1H, 15N-TROSY spectrum, 
stable binding of apo-Atox1 to MBD1-6 was not observed (Figure 4.12).  Rather, we used NMR 
relaxation to determine whether the mobilities of specific MBDs changed in the presence of apo-
Atox1.  We measured the difference in transverse relaxation rates (R2) of the individual MBDs in 
the absence and presence of apo-Atox1.  We demonstrate that the addition of apo-Atox1 
significantly increased the relaxation rates of MBD1 and MBD2, and a lesser extent to other 
MBDs (Figure 4.13).  The large decrease in mobility for MBD1 and MBD2 indicate Atox1-
MBD interaction and is consistent with an increased molecular mass of the complex.  Since 
Atox1 can dock and transfer Cu(I) specifically to MBD2 (Walker, 2004), it can be hypothesized 
that MBD2 is also the main target of apo-Atox1.    
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Figure 4.12: Interaction of apo-Atox1 with MBD1-6 analyzed by 1H, 15N-HSQC 
spectroscopy.  Overlay of 15N MBD1-6 in the absence (black) and presence (red) of apo-Atox1.  
The labeled residues in the spectrum crrespond to free MBD1-6.     
 
 
Figure 4.13: Transverse relaxation rate of MBD1-6 bound to apo-Atox1.  The difference 
between the transverse relaxation rates R2 in the absence and presence of apo-Atox1 plotted as a 
function of residue sequence number.   
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4.5.2 Copper(I) transfer from Atox1 to MBD1-6 increases mobility of MBD1-3.   
 We have used nanobodies to probe the backbone dynamics of MBD1-6.  We 
hypothesized that transient interactions exist between MBD1-3 and that Cu(I) transfer from 
Atox1 to MBD2 disrupts these weak inter-domain interactions, in a similar mechanism to R50 
nanobody binding to MBD3.  To test the Cu(I)-dependent conformational changes in MBD1-6, 
unlabeled Atox1 was pre-treated with Cu(I) at an equimolar molar ratio and subsequently added 
to MBD1-6 at a 6:1 molar ratio.  We observed several chemical shift changes in MBD1-6, 
confirming that Cu(I) was transferred from Atox1 to MBD1-6 (Figure 4.14A). The changes in 
MBD dynamics were measured using NMR relaxation analysis.  We measured the difference in 
transverse relaxation rates (R2) of the individual MBDs in the absence and presence of Atox1-
Cu.  We demonstrate that the transfer of Cu(I) from Atox1 to MBD1-6 caused differences in the 
dynamics of individual MBDs.  The transfer of copper from Atox1 to MBD1-6 caused increased 
mobility of MBD1 and MBD2, and to a lesser extent of MBD3, whereas the mobility of MBD4-
6 remained relatively unaffected (Figure 4.14B).  These results support our hypothesis that 
transient interactions between MBD1-3 are disrupted when Cu(I) is transferred from Atox1 to 
MBD2.  The copper-dependent conformational changes in the MBD1-3 domain group may be 
the first step of the regulatory mechanism of copper transport and trafficking activity.  These 
changes are then relayed to the other cytosolic domains of ATP7B.       
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Figure 4.14: Interaction of Atox1-Cu with MBD1-6 analyzed by 1H, 15N-TROSY 
spectroscopy.  A) Overlay of 15N MBD1-6 in the absence (black) and presence (red) of Atox1-
Cu.  (B) The difference between the transverse relaxation rates R2 in the absence and presence of 
Atox1-Cu plotted as a function of residue sequence number.       
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4.6 Nucleotide-binding and actuator domains do not interact with MBD1-6 
 The N-terminal region of ATP7B is a characteristic region of heavy metal transporters.  
The number of MBDs varies from one or two in bacteria to six in humans, which suggests a 
more complex regulatory function in higher order species.  The interaction of MBD1-6 with 
other cytosolic domains, such as the ATP-binding (ATP-BD) (Tsivkovskii et al., 2000) and 
actuator domain (Gupta et al., 2011), has been suggested to regulate ATP7B copper transport and 
trafficking activity.  It has been demonstrated that ATP-BD interacts with MBD1-6 in a copper 
dependent manner (Tsivkovskii et al., 2000).  The ATP-BD consists of two sub-domains, the 
phosphorylation- and nucleotide-binding domains.  Copper-free MBD1-6 tightly interacts with 
ATP-BD, locking ATP-BD in an inhibited conformation.  However, copper binding to MBD1-6 
decreases this inter-domain interaction, allowing ATP-BD to adopt an active conformation that 
can readily bind ATP.   
 
To test this hypothesis, we tried to detect interactions between ATP-BD and MBD1-6 and 
to map the interaction surface by NMR.   However, the isolated ATP-BD was unfolded, as 
evidenced by poor chemical shift dispersion in a 1H-15N HSQC spectrum (data not shown).  As 
an alternative, we tried to determine whether MBD1-6 interacts with the N-domain, the domain 
responsible for binding ATP (Dmitriev et al., 2006).  The rationale for using the N-domain is that 
the P-domain shows much higher sequence conservation among the different P-type ATPases 
than the N-domain, which suggests that inter-domain interactions may occur at sequences that 
are unique to the N-domain of ATP7B.  Additionally, the N-domain of human Cu-ATPases has a 
large flexible loop that may be important for inter-domain interactions.  Therefore, it is much 
more likely that the N-domain, rather than P-domain, would be the site of inter-domain 
interactions with MBD1-6.  In these experiments, unlabeled MBD1-6 was added in equimolar 
ratio to 15N-labeled N-domain in the absence (Figure 4.15A) and presence of 5 mM ATP (Figure 
4.15B).  We did not observe any chemical shift changes, which indicates that MBD1-6 does not 
interact with N-domain under these conditions.  This is consistent with the results of another 
study (Mondol et al., 2016), which reported no interactions between the N-domain and MBD1-4.  
To explain the discrepancy with the earlier report (Tsivkovskii et al., 2000), a minor population 
of interacting proteins were detected in the pull-down assay (Mondol et al., 2016).  Alternatively, 
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other proteins that were present in the crude cell lysate, but not in the purified NMR sample, may 
be required for MBD interaction with the ATP-BD (Mondol et al., 2016).   
 
Figure 4.15: Potential interaction of MBD1-6 with the 15N-labeled N-domain of ATP7B 
tested by 1H, 15N-HSQC spectroscopy.  Spectra overlay of the 15N N-domain (black) with 
MBD1-6 (red) in the (A) absence and (B) presence of 5 mM ATP.   
 
 
 Based on our nanobody and Atox1-Cu relaxation analysis of MBD1-6, a third alternative 
hypothesis becomes apparent.  We propose that the inter-domain interactions between MBD1-3 
may shield the sites involved in the interactions with the N-domain.  To expose the potential 
binding sites, we examined the interaction between N-domain and the isolated MBDs 1, 2, and 3 
by chemical shift perturbation analysis.  Addition of the N-domain caused some chemical shift 
changes in the spectra of MBD1 (Figure 4.16A) and MBD2 (Figure 4.16B), but not MBD3.  
Mapping the affected residues onto the solution structures shows that the copper-binding motif 
was affected in both MBD1 and MBD2 (Figure 4.16CD).  In addition, the N-terminal region of 
α2 was affected in MBD1.     
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Figure 4.16: Interaction of N-domain with 15N-labeled MBD1 and MBD2.  1H, 15N-HSQC 
spectra of (A) MBD1 and (B) MBD2 before (black) and after (red) the addition of N-domain.  
Regions of (C) MBD1 and (D) MBD2 that are affected by N-domain binding, respectively.     
 
Another study also suggested that MBD1-6 interacts with the A-domain (Gupta et al., 
2011).  The G875R mutation results in unfolding of the A-domain, causing mislocalization of 
ATP7B.  At the basal copper level, G875R-ATP7B is localized to the endoplasmic reticulum 
(ER), instead of the TGN.  When the copper level in the cell increases, G875R-ATP7B migrates 
from the ER to the TGN, restoring normal ATP7B copper transport function.  Since the G875R-
A-domain was unfolded, it was hypothesized that MBD1-6 stabilized G875R-A-domain in a 
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copper-dependent manner (Gupta et al., 2011).  To test this hypothesis, we examined the 
interaction of MBD1-6 with G875R-A-domain in the absence of copper using 1H, 15N-NMR 
spectroscopy.  No chemical shift changes were observed in either MBD1-6 or G875R-A-domain, 
demonstrating that MBD1-6 did not interact with G875R-A-domain (Figure 4.17A).  We also 
analyzed the interaction between wild-type A-domain and MBD1-6 (Figure 4.17B) both in the 
absence and presence of copper and did not observe any spectral changes (Figure 4.17C).  
 
Figure 4.17: Interaction of MBD1-6 with the A-domain of ATP7B analyzed by 1H, 15N 
NMR spectroscopy.  Overlay of 15N (A) G875R-A-domain and (B) wild type A-domain in the 
absence (black) and presence of MBD1-6 (red).  (C) Overlay of 15N MBD1-6 (black) with wild-
type A-domain (red) in the absence (left) and presence (right) of Atox1-Cu.   
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4.7 Glutaredoxin1 preferentially interacts with MBD1 and MBD2 
 Human glutaredoxin1 (hGrx1) has been identified as another protein that interacts with 
and binds to the N-terminus of ATP7B in a copper-dependent manner (Singleton et al., 2010).  
The hGrx1 is a thiol oxidoreducatase that catalyzes the reduction of disulfide bonds.  
Glutathionylation blocks copper binding through the formation of disulfide bridges in the 
cysteine residues of the MBDs.  The hGrx1 catalyzes reduction of the GSSG-MBD disulfides to 
sulfhydryls, which restores Cu(I) binding to the MBDs.  Thus, glutathione and glutaredoxin can 
regulate ATP7B activity through reversible modification of the cysteines in the copper-binding 
CxxC motif.  To confirm whether hGrx1 and the MBDs interact, we used 1H-15N NMR 
spectroscopy to test the interaction.   
 
Glutathione is present in millimolar concentrations in the cell, which may affect the 
binding of redox sensitive proteins to the metal-binding domains.  In the presence of 10 mM 
GSH, we added unlabeled hGrx1 at a 6:1 molar ratio to 15N MBD1-6, which ensured that all the 
MBDs could equally interact with hGrx1.  Using chemical shift perturbation analysis, we 
mapped chemical shift changes, with the majority localized to MBD1 and MBD2 (Figure 4.18B).  
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Figure 4.18: Interaction of MBD1-6 with hGrx1 analyzed by 1H, 15N-HSQC spectroscopy.  
(A) Overlay of 15N MBD1-6 spectra in the absence (black) and presence (red) of hGrx1.  (B) The 
distribution of residues in MBD1-6 that interact with hGrx1.      
 
Interaction of hGrx1 with the first four individual MBDs was subsequently tested to 
determine the specific hGrx1-binding site.  In the presence of 10 mM GSH, we titrated unlabeled 
hGrx1 up to a 2:1 molar ratio to the isotopically labeled individual MBDs.  Interaction of the two 
proteins was monitored by chemical shift perturbation analysis.  Our results show the following 
differences between the interaction of hGrx1 with MBD1 and MBD2.  Significant chemical shift 
changes are observed when hGrx1 was added to MBD1 (Fig 4.19A), whereas a small amount of 
peak volume loss was observed when hGrx1 was added to MBD2 (Figure 4.19B).  Interestingly, 
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no changes were observed when hGrx1 was added to either MBD3 or MBD4 (Figure 4.19CD).  
Despite the highly conserved CxxC copper binding motifs and sequence similarity of all of the 
MBDs, the interaction of hGrx1 appears to be preferential towards MBD1. 
 
Figure 4.19: Interaction of individual MBDs with hGrx1 analyzed by 1H, 15N-HSQC 
spectroscopy.  1H, 15N-HSQC spectra overlay of (A) MBD1, (B) MBD2, (C) MBD3, and (D) 
MBD4 in the absence (black) and presence (red) of hGrx1.   
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4.8 Reaction of cisplatin with MBDs and platinum transfer between the copper-binding 
proteins and redox regulators.  
4.8.1 Cisplatin and carboplatin bind to the CxxC motif of the metal-binding domains and 
form the same reaction product. 
  Overexpression of ATP7B has been implicated in cancer resistance to platinum-
containing drugs.  Using an in vivo bacterial assay, a previous study in our lab demonstrated that 
ATP7B confers cisplatin resistance by trapping cisplatin at the MBDs in the N-terminal region 
(Dolgova et al., 2009).  The expression of a cytosolic fragment containing four metal-binding 
domains (MBD1-4) protected bacterial cells from the toxic effects of cisplatin.  This 
demonstrates that cisplatin sequestration by the MBDs is an effective mechanism for causing 
cisplatin resistance (Dolgova et al., 2009).   To characterize the molecular interactions of 
cisplatin with the MBDs, we analyzed the reactions of cisplatin and a related platinum analogue, 
carboplatin, with MBD2 using NMR chemical shift perturbation analysis.    
 
MBD2 was chosen as the model system to examine the reactions of cisplatin and 
carboplatin because MBD2 is the preferential acceptor of copper from the chaperone protein 
Atox1 (Walker, 2004) and has been demonstrated to bind cisplatin (Dolgova et al., 2009).  
Therefore, we wanted to determine the cisplatin and carboplatin-binding site and analyze the 
structural effects of platinum drug binding to MBD2.  The solution structure of metal-free 
MBD2 was solved, which allowed us map the cisplatin and carboplatin binding site (Dolgova et 
al., 2013).  The cisplatin-binding site was mapped using NMR chemical shift perturbation 
analysis (Figure 4.20A).  Cisplatin binding induced large chemical shift changes in the CxxC 
motif, as well as in regions distant from the copper-binding site (Figure 4.20D).  To confirm the 
location of the cisplatin-binding site, we used an SxxS variant of MBD2, where the cysteines in 
the copper-binding motif were substituted with serine.  As expected, no spectral changes were 
observed when cisplatin was added, confirming that cisplatin binds to the cysteine residues in the 
copper-binding motif (Figure 4.20B).  A higher number of chemical shift changes caused by 
cisplatin is consistent with the larger size of the platinum-derivative compared to the copper ion, 
and may reflect an increased degree of conformational change required in the protein to 
accommodate platinum and its four ligands. Despite having different chemical structures, 
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cisplatin and carboplatin cause identical spectral changes (Figure 4.20C), which indicate that 
these drugs have the same binding mode.  This suggests that ATP7B can confer resistance to 
both drugs through the same mechanism.  Although the MBD2-Pt intermediate is the same for 
both cisplatin and carboplatin, the rates of reaction were significantly different.  Complete 
cisplatin binding was observed within 4 hours, whereas complete binding of carboplatin was 
observed only after several days (Figure 4.21).     
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Figure 4.20: 1H, 15N-HSQC spectra of cisplatin binding to MBD2.  (A) Overlay of apo- 
(black) and cisplatin-bound (red) wild-type MBD2 spectra; (B) Overlay of SxxS-MBD2 with 
(red) and without (black) cisplatin; (C) Overlay of MBD2 reacted with cisplatin (black) and 
carboplatin (red).  (D) Chemical shift changes caused by cisplatin binding to MBD2 as a function 
of amino acid residue number.  (E) Regions of MBD2 that are affected by cisplatin (left) and 
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copper (right) binding.  Chemical shift assignment of C18 and C21 in the cisplatin-bound form 
was not found (*, cyan).   
 
 
Figure 4.21: Time course of cisplatin and carboplatin reactions with MBD2.  
 
4.8.2 Platinum is unidirectionally transferred from Atox1 to MBD2 and can bind to most 
of the metal-binding domains in MBD1-6.   
 Overexpression of ATP7B has been shown to be associated with tumor resistance to 
cisplatin during chemotherapy.  In cells overexpressing ATP7B, its abundance is very low and 
pales in comparison to the concentration of glutathione and other cisplatin scavengers in the cell.  
How then does an increase in ATP7B expression detoxify cisplatin and cause resistance in cells?  
We propose that copper chaperone Atox1 binds cisplatin as it enters the cytoplasm and directly 
transfers the platinum derivative to the MBDs of ATP7B.  To test this hypothesis, we measured 
platinum transfer from Atox1 to MBD2 using 1H, 15N NMR spectroscopy.   
 
 Platinum transfer from Atox1 to MBD2 was monitored by the chemical shift changes in 
both 15N-labeled Atox1 and MBD2.  The metal-free and platinum-bound forms of both Atox1 
and MBD2 have distinct NMR spectra.  This allowed us to simultaneously monitor the 
concentrations of both forms in the platinum transfer experiments.  Initially, unlabeled Atox1 
was pre-treated with cisplatin.  The addition of 15N-labeled MBD2 to unlabeled Atox1-Pt 
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produced chemical shift changes in 15N MBD2 that were almost identical to those caused by free 
cisplatin (Figure 4.22A).  This demonstrates that the reaction of MBD2 with free cisplatin and 
platinum transfer from Atox1 produced the same platinum adduct (Figure 4.22B).  To monitor 
platinum release from Atox1, we repeated this experiment using 15N-labeled Atox1-Pt and 
unlabeled MBD2.  Following the treatment of 15N Atox1 with cisplatin, we observed no residual 
apo-Atox1, confirming that complete cisplatin binding occurred (Figure 4.22C).  After the 
addition of unlabeled MBD2, all of the peaks in the Atox1 spectrum returned back to the 
positions corresponding to the apo form, demonstrating that cisplatin was completely transferred 
to MBD2 and the metal-free, properly folded Atox1 was regenerated.  However, some peaks 
near the copper-binding motif of Atox1 showed loss of intensity, which may reflect 
conformational or chemical exchange (Figure 4.22D).  Interestingly, transfer of platinum was 
unidirectional.  No transfer of platinum from 15N MBD2-Pt to unlabeled Atox1 was observed 
(Figure 4.22EF).   
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Figure 4.22: Transfer of platinum from Atox1 to MBD2 analyzed by 1H, 15N-HSQC 
spectroscopy.  (A) Overlay of MBD2 before (black) and after (red) incubation of Atox1-
cisplatin complex; (B) Overlay of MBD2 incubated with free cisplatin (black) and Atox1-
cisplatin (red); (C) Overlay of Atox1 before (black) and after (red) incubation with cisplatin; (D) 
Overlay of Atox1 before incubation of cisplatin (black) and after (red) addition of unlabeled 
MBD2 to cisplatin-loaded Atox1; (E) Overlay of MBD2 before (black) and after (red) incubation 
with cisplatin at a 1:1 molar ratio; (F) Overlay of MBD2 incubated with free cisplatin before 
(black) and after (red) addition of unlabeled Atox1 at a 2:1 molar ratio.   
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4.8.3 Glutathione and glutaredoxin1 can serve as platinum acceptors from the metal-
binding domains.  
We have previously demonstrated that Atox1 directly transfers cisplatin to the MBDs 
(section 4.9.2).  The MBDs may act as a reservoir by trapping cisplatin in the CxxC motif.  
However, it was unknown whether the MBDs were the final destination for cisplatin.  Rather, 
cisplatin could be transferred on to other terminal acceptors in the cell.  To test this hypothesis, 
we performed platinum transfer experiments from MBD2 to glutathione, glutaredoxin1, and 
thioredoxin1.  These molecules contain cysteine residues in the active site that may remove 
platinum from MBD2 via the ligand-exchange mechanism.  MBD2 was pre-treated with 
cisplatin.  GSH, glutaredoxin1 (hGrx1), or thioredoxin1 (hTrx1) was subsequently added to the 
MBD2-Pt complex and the reaction was monitored by NMR spectroscopy.  We observed a 
gradual return of MBD2-Pt back to its apo form in the presence of 5 mM GSH (Figure 4.23), 
demonstrating that GSH can indeed act as a terminal acceptor and extract platinum bound to the 
MBDs.  Although the rate of platinum removal from the MBDs was slow, MBD2 completely 
returned to its apo form.  The observed rate of MBD2-Pt reaction with glutathione appears to be 
too slow to account for cisplatin detoxification in the cell, which prompted us to investigate other 
potential acceptors such as thioredoxin1 or glutaredoxin1.  These acceptors have a CxxC motif, 
which may extract platinum from the MBDs and contribute to efficient cisplatin detoxification.  
The rate of platinum transfer from MBD2-Pt to hTrx1 or hGrx1 was monitored by 1H, 15N-
HSQC spectroscopy. 
 
Chemical shift perturbation analysis was used to determine the rate of platinum transfer 
from MBD2 to hGrx1 or hTrx1.  MBD2 was preloaded with cisplatin at an equimolar ratio. After 
addition of hGrx1 to MBD2-Pt at an equimolar ratio, we observed a slow rate of platinum release 
to hGrx1 in the first 12 hours, followed by a much faster rate of platinum release between 18 and 
60 hours.  This demonstrates that hGrx1 can be a potential acceptor of platinum from the MBDs.   
In contrast, platinum remains completely bound to MBD2 in the presence of hTrx1 (Figure 
4.23). The lack of platinum transfer to hTrx1 suggests that platinum release from MBD2 is not 
indiscriminate.    
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Figure 4.23: Time course for the return of the MBD2-cisplatin adduct in the presence of 
glutathione, glutaredoxin1, and thioredoxin1.  
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5 Discussion 
5.1 Transient domain interactions within MBD1-3 and MBD5-6 groups. 
The N-terminal region of ATP7B is composed of six metal-binding domains that function 
in the regulation of copper transport and trafficking activity.  Except for MBD1, all the other 
individual metal-binding domain structures of ATP7B had been solved previously.  Each MBD 
has a characteristic ferredoxin-like fold (βαββαβ) and binds one Cu(I) ion between two cysteine 
residues.  The individual MBDs are compact structures that tumble as rigid bodies.  However, to 
fully understand the conformation and dynamics of full-length MBD1-6, the structure of MBD1 
was required.   
 
We solved the structure of MBD1 using high-resolution NMR.  Despite sharing only 
~40-50% sequence similarity with the other MBDs of ATP7B and ATP7A, the structure of 
MBD1 has a ferredoxin-like fold (Figure 5.1).  Similar to the other MBDs, copper binding to 
MBD1 affected the CxxC motif and adjacent residues.  However, copper binding to MBD1 also 
affected the N-terminal region of α2, which was not observed in the other MBDs (Figure 5.1).   
 
Figure 5.1: Structure of MBD1 showing the distances between the sulfur atoms in the CxxC 
copper-binding motif (blue) and the C57xxxxC62 sequence (magenta).   
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Interestingly, there is a specific C57xxxxC62 sequence in the N-terminal region of α2 found only 
in MBD1.  It is unlikely that the C57xxxxC62 sequence is another copper-binding site.  The 
distance between the two sulfurs in the C57xxxxC62 sequence is 8.3 Å apart, which is 3.1 Å 
farther apart than the CxxC copper-binding motif (Figure 5.1).  Additionally, complete binding 
of copper to MBD1 was observed at a 1:1 ratio.  However, copper binding to the CxxC motif in 
the α1-helix may trigger conformational changes that affect the C57xxxxC62 region.  Although 
the C57xxxxC62 sequence is not near the copper-binding motif, the C-terminus of a2-helix is 
significantly closer to the copper-binding motif compared to the other MBDs of ATP7B and 
MBD1 of ATP7A (MNK1) (Figure 5.2).  At the nearest point of contact, the two alpha helices of 
MBD1 are at least 2 Å closer than the other MBDs, indicating that copper-binding to the α1-
helix may trigger conformational changes in the α2-helix.  We also observed that MBD1 
aggregates significantly faster than all of the other purified MBDs and Atox1.  This may suggest 
that the C57xxxxC62 sequence of MBD1 plays a role in inter-domain interactions with the other 
MBDs or cytosolic domains.  This supports a previous hypothesis that hydrogen bond formation 
between the cysteine residues is required to maintain a tight conformation of MBD1-6 (LeShane 
et al., 2010).   
 
NMR structural studies of the metal-binding domains show large conformational 
mobility.  NMR relaxation measurements using shorter MBD constructs demonstrate 
independent dynamics and flexibility between the individual domains (Banci et al., 2008; Fatemi 
et al., 2010).  The individual MBDs of MBD4-6 tumble at different rates, suggesting that the 
MBDs maintain a high degree of flexibility (Fatemi et al., 2010).  In contrast, another study 
suggests that MBD5-6 tumbles as a rigid dumbbell in solution (Achila et al., 2006).  The 
presence of additional MBDs may influence the behavior of shorter MBD constructs, which 
prompted us to investigate the dynamics of full-length MBD1-6.  The narrow linewidths in the 
1H, 15N-TROSY spectrum of MBD1-6 are consistent with rapidly tumbling independent MBDs, 
suggesting a “beads-on-a-string” model (Banci et al., 2009a; Fatemi et al., 2010).  Inter-domain 
flexibility may allow the N-terminal region to interact with other cytosolic domains and facilitate 
copper transfer to MBD5, MBD6, and the transmembrane copper-binding sites.  However, the 
completely independent dynamics of MBD1-6 appears to be inconsistent with previous 
biochemical studies.      
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Figure 5.2:  Structural comparison of MBD1 (green) with MBD2 (orange), MBD3 (cyan), 
and MNK1 (magenta).  The distances shown are the nearest contact points between the copper-
binding motif in α1 and the C-terminal region of α2.    
 
Biochemical studies demonstrated copper-dependent conformational changes in MBD1-
6.  Cysteine to alanine mutations in the copper-binding motif of MBD2 and MBD3 caused 
oxidation in other MBDs, resulting in the total loss of copper binding (LeShane et al., 2010).  
Inter-domain hydrogen bonding at the cysteine residues was hypothesized to keep a tight 
conformation of MBD1-6.  Investigating domain-domain interactions is particularly challenging 
because the individual MBDs are highly mobile, as indicated by the narrow linewidths in the 1H, 
15N-TROSY spectrum of MBD1-6.  To investigate the domain-domain interactions observed in 
the N-terminal region of ATP7B, we used nanobodies as a tool to probe the backbone dynamics 
and transient interactions of the individual MBDs in full-length MBD1-6.   
 
  Nanobodies are isolated single variable domains of heavy-chain antibodies.  The 
nanobodies that were produced are highly soluble, monomeric proteins that specifically bind to 
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MBD1-6.  The small size of the nanobodies is particularly advantageous in NMR transverse 
relaxation studies because the binding of a nanobody to a specific domain does not decrease the 
quality of the MBD1-6 1H-15N TROSY spectra.  The rationale for using nanobodies in our 
analysis is that binding of a nanobody to a specific MBD may change the dynamic properties for 
a specific group of MBDs.  A change in the mobility of specific MBDs is reflected in the 
transverse relaxation rate.  Our work reveals important structural and dynamic interactions that 
may explain the regulation of ATP7B copper transport and trafficking activity (Huang et al., 
2014).  Contrary to previous studies (Fatemi et al, 2010; Banci et al., 2009a), our NMR 
relaxation experiments demonstrated that MBD1-6 does not resemble a complete “beads-on-a-
string” model.  Rather, MBD1-3 is a correlated group of interacting MBDs with distinct dynamic 
characteristics compared to the other metal-binding domains.  Binding of the R50 nanobody to 
MBD3 decreased the mobility of that specific domain, which is consistent with an increased 
molecular mass of the complex.  Interestingly, the mobility of MBD1 and MBD2 significantly 
increased.  This suggests that R50 nanobody binding  
 
Figure 5.3: Model of the metal-binding domain interactions in the N-terminal region of 
ATP7B.  Nanobodies have identified transient interactions (red arrows) between two groups of 
metal-binding domains, MBD1-3 (in this work) and MBD5-6 (previously).  The dynamics of 
MBD4 is largely independent.       
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to MBD3 disrupts the transient interactions between MBD1-3, which cause increased dynamic 
independence of MBD1 and MBD2.  R50 binding did not change the correlation times of MBD5 
and MBD6.  This is consistent with previous studies suggesting that MBD5-6 forms a separate 
structural unit (Achila et al., 2006).  In contrast, when the 1R1 nanobody was bound to MBD4, 
the mobility of all the domains decreased to a similar extent.  This suggests that the slower 
tumbling of the 1R1 nanobody-MBD4 complex is partially propagated to the other MBDs.  The 
lack of distinct mobility changes in the MBDs suggests that the dynamics of MBD4 is highly 
independent and does not interact with other MBDs.  MBD4 of rats cannot bind copper because 
it does not have the signature CxxC copper-binding motif, suggesting that MBD4 does not have 
an essential role in copper transfer.  MBD4 may exclusively function as a structural link between 
two groups of correlated domains, MBD1-3 and MBD5-6.  
 
To completely investigate the dynamics of the N-terminal region, we characterized a 
panel of 14 additional nanobodies that bind to the MBDs.  We mapped all the nanobody-binding 
sites by chemical shift perturbation analysis and estimated the nanobody-binding affinities from 
the chemical exchange regime of the MBD-nanobody complexes.  All the nanobodies tested bind 
to either MBD3 or MBD4, which suggests that these MBDs are more exposed in full-length 
MBD1-6, leading to higher immunogenicity of these domains.  Nanobodies against MBD3 bind 
tightly and specifically to the C-terminal region of the α1 helix (Huang et al., 2014), suggesting 
that the folding of MBD1-3 exposes a single well-defined epitope.  In contrast to MBD3, there is 
a wide range of binding epitopes and affinities for nanobodies that are produced against MBD4.  
This variability is consistent with independent dynamics of MBD4, resulting in higher surface 
exposure in full-length MBD1-6.   
 
To obtain a more detailed model of MBD1-6 conformation and dynamics, we can 
investigate other transient interactions using nanobodies that bind to other MBDs.  Although we 
only tested nanobodies against MBD3 or MBD4, phage display is a powerful technique for 
selecting nanobodies that bind to the other MBDs.  Using the original cDNA library containing 4 
x 108 independent clones that specifically bind to MBD1-6, we can select for nanobodies against 
a desired MBD.  For example, to select for nanobodies against MBD1, we purify MBD1 and use 
that domain as an antigen for new rounds of positive selection by phage display.  Since 
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nanobodies against MBD4 appear to be prevalent in the library, MBD4 can be used for negative 
selection.  Our studies demonstrate that nanobodies are an effective tool for probing the 
conformation and dynamics of multi-domain proteins.   
5.2 Regulation of ATP7B activity through domain-domain interactions.  
 The N-terminal region of ATP7B functions in the regulation of copper transport and 
trafficking activity.  However, the precise molecular mechanism for regulating ATP7B activity 
by the N-terminal region is not well characterized.  All the metal-binding domains have similar 
structures, but different groups of metal-binding domains have distinct functions.  Only MBD5 
and MBD6, the metal-binding domains closest to the transmembrane region, are essential for 
copper transport and trafficking activity (Cater et al., 2004; Huster, 2003).  MBD1-4 was 
proposed to regulate ATP7B activity by controlling copper access to functionally important 
metal-binding sites (Huster, 2003).   
 
 All of the individual MBDs have similar structural folds and copper-binding properties.  
Each MBD binds one Cu(I) ion between two cysteine residues in a linear distorted geometry 
(DiDonato et al., 2000; Ralle et al., 2004).  Although absolute values of copper-binding affinity 
to each MBD depend on the method used, the relative affinities of all the MBDs were found to 
be similar in each study (Banci et al., 2010; Wernimont, 2003; Yatsunyk and Rosenzweig, 2007).  
Since there is no specific MBD with a significantly higher copper-binding affinity, the 
mechanism of copper transfer to functionally important metal-binding sites such as MBD5 and 
MBD6 is not clear.  One mechanism may involve inter-domain copper transfer.  Docking of 
Atox1-Cu to MBD2 may trigger conformational changes in the N-terminal region, allowing 
upstream copper acceptor sites to transfer copper to MBDs 5 and 6 (Achila et al., 2006).  
Recognition of the partner protein in the copper transfer reaction may be mediated through 
electrostatic interactions.  An alternative mechanism may involve the direct transfer of copper 
from Atox1 to all of the MBDs (Banci et al., 2009a; LeShane et al., 2010; Yatsunyk and 
Rosenzweig, 2007).  However, we cannot exclude the possibility that Atox1 can directly transfer 
copper to the transmembrane binding site.   The bacterial copper chaperone, CopZ, activates the 
enzymatic activity of the Archaeoglobus fulgidus Cu+-ATPase, CopA, by directly transferring 
copper to the transmembrane binding sites (González-Guerrero and Argüello, 2008).    
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We previously demonstrated that transient interactions exist between MBD1-3 and are 
disrupted by nanobody binding.  Our results demonstrate that copper binding to MBD1-6 indeed 
disrupts transient interactions between MBD1-3 in a similar mechanism as R50 nanobody 
binding to MBD3 (Figure 5.4). We observed a decrease in mobility in both MBD2 and MBD1 
when apo-Atox1 is added to MBD1-6.  This result is consistent with previous studies 
demonstrating that MBD2 preferentially interacts with Atox1 (Walker, 2004).  Since there is a 
short linker of 13 amino acids between MBD1 and MBD2, the slower tumbling caused by the 
increased molecular weight of the Atox1-MBD2 complex may propagate to MBD1, thereby, 
decreasing the mobility of that domain.  In contrast, the mobility of MBD1, MBD2, and MBD3 
increase when copper is transferred from Atox1 to MBD1-6.  The increased dynamic 
independence of MBD1-3 confirms our hypothesis that transient interactions exist between 
MBD1-3 and are disrupted when copper binds (Huang et al., 2014).    
 
Taken together, our transverse relaxation data of MBD1-6 allow us to propose a model 
for the regulation of ATP7B copper transport and trafficking activity.  Transient interactions 
restrict copper access to MBD1-3 (Figure 5.5A).  Under copper limiting conditions, copper is 
transferred from Atox1 to MBD2, which is the preferred docking site for Atox1 (Walker, 2004).  
The transfer of copper to MBD2 disrupts the weak inter-domain interactions between MBD1-3, 
causing increased dynamic independence of MBD1 and MBD3 (Figure 5.5B).  The increased 
dynamics of MBD1-3 changes the orientation of the connecting loops, which may increase 
copper accessibility to the other MBDs (Figure 5.5C).  MBD5 and MBD6 may acquire copper 
directly from Atox1 (Figure 5.5D) or by inter-domain copper transfer from upstream acceptor 
sites such as MBD1-3 (Figure 5.5E).   
 
An additional mechanism for regulating ATP7B activity involves the interaction of the 
MBDs with the other cytosolic domains.  It has been demonstrated that the N-terminal region of 
ATP7B interacts with the ATP-BD (Tsivkovskii et al., 2000).  The authors proposed that the 
MBDs hold ATP-BD in a specific conformation (Tsivkovskii et al., 2000).  Copper binding 
releases the MBDs from ATP-BD.  ATP-BD subsequently adopts a conformation with a high 
ATP binding-affinity (Tsivkovskii et al, 2000).  This is in agreement with our model 
demonstrating that copper binding disrupts inter-domain interactions between MBD1-3.  After 
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Cu(I) binds to MBD2, conformational changes in MBD1-3 triggers the release of MBD1-6 from 
ATP-BD.   
 
 
Figure 5.4: The effect of (A) R50 nanobody and (B) copper-binding on the domain 
dynamics of MBD1-6.    
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Additionally, a previous study suggested that the metal-binding domains interact with the 
G875R A-domain in a copper-dependent manner (Gupta et al., 2011). The G875R A-domain is 
unfolded, resulting in mislocalization of ATP7B to the endoplasmic reticulum.  The MBDs were 
hypothesized to provide extra rigidity to the G875R A-domain.  However, we did not observe 
any interaction between the N-terminal region and the A-domain.  In the N-terminal region of 
ATP7B, there is a 63 amino acid sequence that is upstream from the first metal-binding domain 
(Guo, 2005).  This 63 amino acid sequence is responsible for correctly targeting ATP7B to the 
apical membrane in polarized cells (Guo, 2005).  It could be hypothesized that the N-terminal 63 
amino acid residues actually interact with the other cytosolic domains and not the specific metal-
binding domains.     
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Figure 5.5: The proposed mechanism for the regulation of ATP7B activity.  (A) Transient 
interactions restrict copper access to MBD1-3.  (B) Atox1 transfers Cu(I) to MBD2 and disrupts 
the transient interactions, causing increased mobility of MBD1 and MBD3 (red arrows).  (C) 
Other MBDs become more accessible for Cu(I) binding.  A copper saturated state occurs by 
either (D) direct transfer of copper from Atox1 or (E) inter-domain copper transfer from MBD1-
3.  This conformation maintains the electrostatic repulsion between the MBDs and the other 
cytosolic domains (pink arrow), which increases copper transport activity and triggers copper-
dependent trafficking of ATP7B.   
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5.3 Platinum and copper interact with the metal-binding domains of ATP7B via the 
same mechanism.    
 Cisplatin is a widely used anti-cancer drug; however, intrinsic and acquired resistance 
limit its effectiveness.  Several copper transport proteins can bind cisplatin and are implicated in 
a variety of cisplatin resistance mechanisms.  The copper transporter hCtr1 has been shown to 
mediate the uptake of cisplatin (Ishida et al., 2002).  Atox1 is a copper chaperone that binds 
cisplatin both in vitro (Palm et al., 2011) and in vivo (Arnesano et al., 2011) at the signature 
CxxC motifs.  Lastly, overexpression of ATP7B is associated with tumor resistance to cisplatin 
during chemotherapy.  Our lab previously demonstrated that the metal-binding domains 
efficiently detoxified cisplatin without actively transporting it out of the cell (Dolgova et al., 
2009).  However, it was unclear how cisplatin actually reached the metal-binding domains of 
ATP7B.  We propose that cisplatin utilizes the copper transport pathway by hijacking the Atox1-
ATP7B copper transport route.  This may allow Atox1 to directly deliver cisplatin to the MBDs 
of ATP7B.  To test this hypothesis, we measured cisplatin transfer from Atox1 to MBD2.  Since 
Atox1 specifically delivers copper to MBD2 (Walker, 2004), this domain was chosen as a small 
model system to examine the interactions with cisplatin.  
 
It was previously reported that cisplatin-induced Atox1 unfolding may be a possible 
cisplatin resistance mechanism (Palm et al., 2011).  However, this study was performed with 
higher cisplatin to protein ratios.  With the large number of molecular components in the cell that 
can bind cisplatin, it is unlikely that multiple cisplatin molecules can bind to one specific protein 
and induce homo-oligomerization.  No protein unfolding during the course of the NMR 
experiments was observed in our experimental conditions.  
 
We successfully demonstrated that Atox1 directly transferred cisplatin to MBD2.  Unlike 
copper transfer between Atox1 and MBD2, which is reversible, cisplatin transfer to MBD2 was 
unidirectional.  This suggests that the MBDs can serve as a kinetic trap by stabilizing the four 
ligands that are attached to platinum.  This transfer mechanism may also be applicable for 
another platinum analog, carboplatin.  We demonstrated that carboplatin formed the same 
platinum adduct with MBD2, suggesting that ATP7B can confer resistance to both drugs through 
the same mechanism.  
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To increase the effectiveness of cisplatin detoxification by the metal-binding domains of 
ATP7B, Atox1 may also transfer cisplatin to the other MBDs.  This hypothesis was recently 
supported by a study demonstrating that Atox1 transferred cisplatin to MBD4 of ATP7B (Palm-
Espling et al., 2013).  However, contrary to our studies, a heterodimer was also formed between 
Atox1 and MBD4 during platinum transfer (Palm-Espling et al., 2013).  Differences in 
incubation times for Atox1-Pt may explain the shift towards heterodimer formation in MBD4.  It 
was suggested that increasing the incubation time between Atox1-Pt and MBD4 decreased the 
amount of platinum transferred between Atox1 and MBD4 (Palm-Espling, 2013).  This 
observation is consistent with our results.  Atox1-Pt was incubated with MBD2 for two hours in 
our experimental conditions, whereas the reported study incubated Atox1-Pt with MBD4 for 
twice as long.  
 
Our study demonstrates that Atox1 binds and transfers cisplatin to the MBDs of ATP7B.  
However, it is well established that the main physiological function of Atox1 is to deliver copper 
to the MBDs.  If both cisplatin and copper are present in the cell, how does Atox1 determine 
which metal to bind?  A recent study demonstrated that monomeric Atox1 forms a di-metal 
complex by binding both copper and platinum simultaneously at the CxxC motif (Palm-Espling 
et al., 2013).  This study also proposes that cisplatin may hitchhike with copper onto Atox1 
instead of completely occupying the single metal-binding site.  However, it is unknown which 
metal, if any, can be transferred from copper- and cisplatin-bound Atox1 to the metal-binding 
domains.  Our studies demonstrate that cisplatin utilizes the copper transport pathway by binding 
to Atox1 for subsequent delivery to the MBDs of ATP7B.   
 
5.4 Transfer of platinum along the copper transport pathway serves as a mechanism of 
cisplatin detoxification in the cell. 
 We have demonstrated that Atox1 binds and transfers cisplatin to the MBDs of ATP7B, 
in a process that parallels the copper transport pathway.  Since ATP7B has several potential 
cisplatin binding sites, the transfer of platinum to the MBDs serves as an efficient mechanism for 
cisplatin detoxification.  When cisplatin reaches ATP7B, two possible mechanisms have been 
proposed in the detoxification of cisplatin.  One mechanism is the active transport of cisplatin out 
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of the cell catalyzed by ATP7B (Safaei et al., 2007; Tadini-Buoninsegni et al., 2013).  The other 
mechanism involves cisplatin being trapped at the MBDs (Dolgova et al., 2013; 2009).  
Although ATP7B is known to transport copper across the cell membrane, cisplatin transport 
using the same mechanism is not an efficient process.  Platinum transport was observed in Sf9 
cells expressing functional ATP7B (Safaei et al., 2007).  The maximal platinum transport rate 
was 30 pmol/mg protein/min measured at a non-physiological pH of 4.6.   This rate was also pH 
dependent, as the cisplatin transport rate was almost negligible near physiological pH (Safaei et 
al., 2007).   
 
The low cisplatin transport rate at physiological pH suggests that active extrusion may 
not be the primary mechanism for cisplatin detoxification.  Rather, we propose that a more likely 
in vivo cisplatin resistance mechanism involving ATP7B is the sequestration of cisplatin at the 
metal-binding domains.  Our lab previously demonstrated that a protein construct expressing the 
first four metal-binding domains (MBD1-4) was sufficient to confer cisplatin resistance in E. coli 
cells (Dolgova et al., 2009).   Using a simple in vivo assay, platinum binding to DNA can be 
monitored by the formation of E. coli cell filaments.  When MBD1-4 was expressed, cell 
filamentation was not observed, demonstrating that the MBDs can exert a protective effect 
against cisplatin.  Since MBD1-4 is entirely cytosolic in the cell, cisplatin detoxification is likely 
mediated by platinum sequestration in the metal-binding domains and not active extrusion out of 
the E. coli cell.   
 
 The six metal-binding sites in ATP7B increase the total cisplatin binding capacity.  
However, the abundance of ATP7B is still low even in cells overexpressing ATP7B.  How then 
does a limited number of approximately 500 ATP7B molecules per cell (Beck et al., 2011) 
detoxify cisplatin and cause resistance in cells? We propose that the metal-binding domains may 
not be the final destination for cisplatin.  Rather, the MBDs serve as a high-affinity reservoir for 
cisplatin molecules that can transfer platinum to other abundant proteins or small molecule 
acceptors in a non-toxic form.  To test this hypothesis, we measured platinum release from 
MBD2 to other potential terminal acceptors such as glutathione, glutaredoxin1, and thioredoxin1.    
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 We observed a gradual return of cisplatin-bound MBD2 back to its apo form in the 
presence of GSH or human glutaredoxin.  This demonstrates that GSH and hGrx1 can be 
potential acceptors by extracting platinum bound to the MBDs.  Despite having a CxxC motif, 
hTrx1 cannot strip platinum off MBD2, suggesting that platinum transfer is not indiscriminate.  
Specific protein-protein interactions with an even higher cisplatin binding affinity than MBD2 
may be required to strip platinum off the MBDs.  The quantitative cisplatin-binding affinities for 
hGrx1 have not been determined; however, hGrx1 is a likely candidate as an intermediate 
acceptor in the cell because it has been shown to specifically interact with the MBDs at the CxxC 
motif (Singleton et al., 2010). 
 
The ability for GSH to extract platinum from the MBDs is more complicated.  GSH has 
the lowest copper binding affinity among the copper-binding proteins (Banci et al., 2010).  If 
cisplatin transport follows the same copper binding affinity gradient, how can GSH strip 
platinum off the MBDs? A possible explanation may be that copper and platinum react 
differently upon binding to various cellular components.  Copper(I) does not change chemically 
when it reacts with different proteins in the cell.  Cu(I) remains bound by two ligands in a 
distorted linear geometry.  In contrast, the ligands attached to platinum are substituted by 
different moieties depending on the protein it binds to.  Therefore, the different combination of 
ligands that are bound to platinum may cause some of these reactions to be kinetically 
irreversible.               
 
 Taken together, our data allows us to propose a mechanism of cisplatin detoxification by 
ATP7B.  We propose that there are two branches of cisplatin transport in the cell, both mediated 
through Atox1.  One pathway leads to cisplatin detoxification through ATP7B (Figure 5.6A; red 
arrow).  The other pathway involves cisplatin delivery to the nucleus, causing cell death (Figure 
5.6A; blue arrow).  Therefore, cell sensitivity to cisplatin is determined by the balance of 
cisplatin delivery to ATP7B or to the nucleus.         
   
The direct transfer of platinum from Atox1 to the MBDs parallels copper distribution 
within cells and allows us to explain how moderate levels of ATP7B overexpression can lead to 
cisplatin resistance.  Cisplatin enters the cell through the passive copper channel, hCtr1.  Atox1 
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binds cisplatin at the entry site from the C-terminal region of hCtr1, which prevents cisplatin 
sequestration by glutathione and other low-affinity acceptors in the cytosol (Figure 5.6B; black 
arrow).  Atox1 also functions as a copper-responsive transcription factor that can translocate into 
the nucleus and bind to DNA (Itoh et al., 2008; Muller and Klomp, 2009).  This suggests that 
Atox1 may deliver cisplatin into the nucleus, causing various Pt-DNA crosslinks.  Concurrently, 
a fraction of Atox1-Pt is also delivered to the MBDs of ATP7B.  Platinum is then gradually 
released to other acceptors such as glutathione and glutaredoxin in a non-toxic form (Figure 
5.6B; red dashed arrow).   This mechanism may predominate at low cisplatin concentrations in 
the cell during chemotherapy.  As ATP7B expression increases, so does the amount of cisplatin 
interacting with the MBDs, which decreases the potential amount of cisplatin reacting with 
DNA.  This supports the correlation between increased ATP7A/ATP7B expression and cisplatin 
resistance (Figure 5.6B; red arrow). However, in our experimental work, much higher cisplatin 
concentrations were used.  At higher cisplatin concentrations, the Atox1-Pt transport mechanism 
may become overwhelmed.  This may cause excess platinum to indiscriminately bind to GSH, 
metallothionein, or other low-affinity acceptors.    
 
Since the cisplatin and copper transport pathways are intertwined, it may be possible to 
reduce cisplatin detoxification by manipulating the copper status in the cell.  Copper induces the 
downregulation of its own influx transporter, hCtr1 (Molloy and Kaplan, 2009).  By decreasing 
the copper concentration in the cell, the amount of hCtr1 at the plasma membrane is maximized 
for cisplatin uptake.  When cisplatin was used in combination with a copper chelator, 
tetrathiomolybdate, tumor cell sensitivity to cisplatin increased by two-fold (Ishida et al., 2010).  
Increased cisplatin uptake into the cell would allow Atox1 to bind and transfer more cisplatin to 
the nucleus.  Therefore, combinational therapy with cisplatin and copper chelators may lead to 
safer and more effective platinum-based chemotherapy.   
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Figure 5.6: Cisplatin transfer from Atox1 to the MBDs leads to cisplatin detoxification.  (A) 
Atox1 binds and transfers cisplatin to the nucleus (blue arrow) and a small fraction to the MBDs 
(red arrow).  (B) As ATP7B is overexpressed, the fraction of cisplatin transferred to the MBDs 
also increases (red arrow).  This reduces the amount of cisplatin reaching the nucleus (blue 
arrow), thereby, facilitating cisplatin resistance.  Platinum or a platinum derivative can be 
subsequently transferred from the MBDs to other acceptors such as glutathione and 
glutaredoxin1 (red dashed arrow).  
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6 Conclusions 
We have demonstrated that cisplatin can be transferred in the cell along the copper 
transport pathway by hijacking copper chaperone Atox1.  We have shown that copper and 
platinum share the same mechanism of interaction with the metal-binding domains of ATP7B.  
We have also demonstrated that ATP7B can confer resistance to different platinum analogs 
through the same mechanism.  We have proposed an effective mechanism of cisplatin 
detoxification in the cell mediated by ATP7B and have identified potential acceptors that can 
strip platinum off the MBDs.   
 
 We have solved the solution structure of MBD1, the only metal-binding domain whose 
structure was missing in ATP7B.  We have demonstrated the potential of nanobodies as tools to 
study protein dynamics.  This is a novel method that has helped us identify transient interactions 
between MBD1-3.  The disruption of these transient interactions between MBD1-3 may be the 
key initial step for regulating ATP7B copper transport and trafficking activity.  We have 
demonstrated copper dependent conformational transitions in MBD1-6 that led us to a structure-
based model of ATP7B regulation by copper.     
  
7 Future directions 
  In this work, we have identified two groups of dynamically correlated domains, 
MBD1-3 and MBD5-6, which are involved in the regulation of ATP7B copper transport and 
trafficking activity.  Investigating how MBD1-3 is positioned in space relative to MBD5-6 may 
help us understand how these downstream metal-binding domains acquire copper.  Residual 
dipolar couplings and paramagnetic relaxation enhancement are two NMR techniques that can be 
used to build a more precise model of MBD1-6 conformation and dynamics.  Also, nanobodies 
that bind to other MBDs can be used to gain a complete picture of the transient interactions that 
exist within MBD1-6.  Our studies have demonstrated that the disruption of transient interactions 
between MBD1-3 is the initial step for regulating ATP7B activity.  However, it is unclear what 
the subsequent steps are in the mechanism of ATP7B copper transport.  Does Atox1 directly 
transfer copper to MBD5, MBD6, or the transmembrane region?  Is inter-domain copper transfer 
to MBD5-6 the predominant mechanism for activating ATP7B activity?  We can test this 
hypothesis by examining whether Atox1-Cu can activate the copper transport activity of ATP7B 
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by selectively mutating cysteine residues in either MBD1-3 or MBD5-6.            
 
  To test our hypothesis that the Atox1-ATP7B copper transport pathway diverts 
platinum away from the nucleus, it is necessary to examine whether Atox1 can enter the nucleus 
and deliver cisplatin to DNA.  The rate of platinum transfer from MBD2 to GSH or hGrx1 may 
be too slow to effectively detoxify cisplatin in the cell.  We can investigate other potential 
acceptors that can remove platinum at a much faster rate from the MBDs.   
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